Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-let-7a-5p | AKT2 | -1.37 | 0 | 0.16 | 0.1135 | TargetScan | -0.12 | 0 | NA | |
| 2 | hsa-miR-29a-3p | AKT2 | 0.1 | 0.5732 | 0.16 | 0.1135 | MirTarget | -0.1 | 4.0E-5 | 24076586 | Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis |
| 3 | hsa-miR-106b-5p | AKT3 | 1.47 | 0 | -1.44 | 0 | miRNATAP | -0.16 | 0.00426 | NA | |
| 4 | hsa-miR-107 | AKT3 | 0.66 | 0 | -1.44 | 0 | PITA; miRanda | -0.26 | 0.0031 | NA | |
| 5 | hsa-miR-146b-5p | AKT3 | 1.09 | 1.0E-5 | -1.44 | 0 | miRNAWalker2 validate | -0.15 | 0.00189 | NA | |
| 6 | hsa-miR-15a-5p | AKT3 | 1.63 | 0 | -1.44 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.41 | 0 | NA | |
| 7 | hsa-miR-16-5p | AKT3 | 0.75 | 0 | -1.44 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.27 | 0.0001 | NA | |
| 8 | hsa-miR-17-5p | AKT3 | 2.07 | 0 | -1.44 | 0 | TargetScan; miRNATAP | -0.22 | 0 | NA | |
| 9 | hsa-miR-181a-5p | AKT3 | -0.38 | 0.05621 | -1.44 | 0 | miRNATAP | -0.23 | 9.0E-5 | NA | |
| 10 | hsa-miR-181b-5p | AKT3 | 0.67 | 0.00024 | -1.44 | 0 | miRNATAP | -0.37 | 0 | NA | |
| 11 | hsa-miR-20a-5p | AKT3 | 2.65 | 0 | -1.44 | 0 | miRNATAP | -0.24 | 0 | NA | |
| 12 | hsa-miR-22-3p | AKT3 | 1.43 | 0 | -1.44 | 0 | miRNATAP | -0.26 | 0.00109 | NA | |
| 13 | hsa-miR-29b-2-5p | AKT3 | 0.35 | 0.19484 | -1.44 | 0 | mirMAP | -0.18 | 2.0E-5 | NA | |
| 14 | hsa-miR-29b-3p | AKT3 | 3.11 | 0 | -1.44 | 0 | miRNATAP | -0.27 | 0 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
| 15 | hsa-miR-3065-5p | AKT3 | 0.65 | 0.09995 | -1.44 | 0 | mirMAP | -0.18 | 0 | NA | |
| 16 | hsa-miR-362-5p | AKT3 | 0.66 | 0.02433 | -1.44 | 0 | PITA; TargetScan; miRNATAP | -0.23 | 0 | NA | |
| 17 | hsa-miR-542-3p | AKT3 | 1.62 | 0 | -1.44 | 0 | miRanda | -0.19 | 1.0E-5 | NA | |
| 18 | hsa-miR-93-5p | AKT3 | 1.51 | 0 | -1.44 | 0 | miRNATAP | -0.25 | 0 | NA | |
| 19 | hsa-let-7a-5p | HRAS | -1.37 | 0 | 0.14 | 0.35812 | miRNAWalker2 validate; miRTarBase | -0.14 | 0.00016 | 18344688; 20033209; 20607356; 23134218; 19323605 | Using an established orthotopic mouse lung cancer model we show that intranasal let-7 administration reduces tumor formation in vivo in the lungs of animals expressing a G12D activating mutation for the K-ras oncogene;k-Ras and c-Myc two key oncogenes in lung cancer have been found to be targeted by let-7 in vitro; The aim of the present study is to determine the effect of let-7a a member of let-7 family on the growth of lung cancer in vivo and to investigate whether let-7-induced suppression of k-Ras and c-Myc is involved in lung cancer; Overexpression of let-7a can inhibit the growth of lung cancer transplanted subcutaneously in nude mice by suppression of k-Ras and c-Myc;Transfection of let-7 miRNA reduced expression of pan-RAS N-RAS and K-RAS in the glioblastoma cells;MicroRNA let 7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K Ras and HMGA2 gene expression; K-RAS and HMGA2 mRNA levels were significantly higher in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; However the protein levels of K-RAS and HMGA2 were significantly lower in the let-7a overexpressed group than those in the let-7a inhibited group p < 0.05; We suppose that let-7a inhibits the proliferation and invasion of the cell line 95D by regulating the translation of K-RAS and HMGA2 mRNA not the transcription of the mRNA itself;Because let-7 microRNA targets the K-ras oncogene we aimed to characterize let-7 expression and function in PDAC in vitro and in vivo; Restoring let-7 levels in cancer-derived cell lines strongly inhibits cell proliferation K-ras expression and mitogen-activated protein kinase activation but fails to impede tumor growth progression after intratumoral gene transfer or after implantation of Capan-1 cells stably overexpressing let-7 microRNA |
| 20 | hsa-miR-143-3p | HRAS | -1.21 | 1.0E-5 | 0.14 | 0.35812 | miRNAWalker2 validate; miRTarBase | -0.13 | 0 | 21276449 | The Evi1 microRNA 143 K Ras axis in colon cancer |
| 21 | hsa-miR-940 | JMJD7-PLA2G4B | 0.01 | 0.97493 | -0.4 | 0.03394 | miRNATAP | -0.12 | 2.0E-5 | NA | |
| 22 | hsa-miR-15a-5p | KDR | 1.63 | 0 | -1.29 | 1.0E-5 | miRNATAP | -0.28 | 8.0E-5 | NA | |
| 23 | hsa-miR-16-5p | KDR | 0.75 | 0 | -1.29 | 1.0E-5 | miRTarBase; miRNATAP | -0.3 | 0.00018 | 26934556 | The expression levels of two target genes Myb and VEGFR2 were affected significantly by miR-16 while glucose administration inhibited miR-16 expression and enhanced tumor cell proliferation and migration; Hyperglycemia can impact the clinical outcomes of CRC patients likely by inhibiting miR-16 expression and the expression of its downstream genes Myb and VEGFR2 |
| 24 | hsa-miR-19b-1-5p | KDR | 1.71 | 0 | -1.29 | 1.0E-5 | miRNAWalker2 validate | -0.22 | 0.00036 | NA | |
| 25 | hsa-miR-200c-3p | KDR | 0.38 | 0.08422 | -1.29 | 1.0E-5 | miRNATAP | -0.27 | 1.0E-5 | 24205206 | MiR 200c increases the radiosensitivity of non small cell lung cancer cell line A549 by targeting VEGF VEGFR2 pathway; MiR-200c at the nexus of epithelial-mesenchymal transition EMT is predicted to target VEGFR2; The purpose of this study is to test the hypothesis that regulation of VEGFR2 pathway by miR-200c could modulate the radiosensitivity of cancer cells; Bioinformatic analysis luciferase reporter assays and biochemical assays were carried out to validate VEGFR2 as a direct target of miR-200c; We identified VEGFR2 as a novel target of miR-200c |
| 26 | hsa-miR-429 | KDR | 2.38 | 0 | -1.29 | 1.0E-5 | PITA; miRanda; miRNATAP | -0.11 | 0.00976 | NA | |
| 27 | hsa-miR-590-3p | KDR | 0.84 | 0.00129 | -1.29 | 1.0E-5 | miRanda | -0.24 | 6.0E-5 | NA | |
| 28 | hsa-miR-590-5p | KDR | 2.07 | 0 | -1.29 | 1.0E-5 | miRanda | -0.25 | 2.0E-5 | NA | |
| 29 | hsa-let-7a-3p | KRAS | 0.17 | 0.43183 | 0.54 | 0.00142 | mirMAP; miRNATAP | -0.17 | 5.0E-5 | 24727325; 20603437; 24890702; 23324806; 21994416; 23167843; 27620744; 20177422; 25183481; 22584434; 18922928 | Association study of the let 7 miRNA complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer NCCTG N0147 Clinical Trial; A let-7 microRNA-complementary site LCS6 polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression;A let 7 microRNA binding site polymorphism in 3' untranslated region of KRAS gene predicts response in wild type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy; A polymorphism in a let-7 microRNA complementary site lcs6 in the KRAS 3' untranslated region UTR is associated with an increased cancer risk in non-small-cell lung cancer and reduced overall survival OS in oral cancers; the presence of KRAS let-7 lcs6 polymorphism was evaluated in 130 mCRC patients who were enrolled in a phase II study of cetuximab monotherapy IMCL-0144; KRAS let-7 lcs6 polymorphism was found to be related to object response rate ORR in mCRC patients whose tumors had KRASwt;Let 7 microRNA binding site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta analysis; There is a small but growing body of literature regarding the predictive utility of a Let-7 microRNA-binding-site polymorphism in the 3'-untranslated region UTR of KRAS KRAS-LCS6 for colorectal cancer outcome although the results are conflicting; A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism LCS6; rs61764370 and colorectal cancer outcome;The LCS6 polymorphism in the binding site of let 7 microRNA to the KRAS 3' untranslated region: its role in the efficacy of anti EGFR based therapy in metastatic colorectal cancer patients; The lethal-7 let-7 family of microRNAs regulates KRAS activity; We studied the association of the KRAS let-7 LCS6 polymorphism with the response in 100 refractory mCRC patients treated with anti-EGFR antibodies; The KRAS let-7 LCS6 polymorphism was genotyped using the BioMark system in blood and tumor DNA samples; The KRAS let-7 LCS6 G-allele showed a statistically significant association with nonresponse to anti-EGFR-based treatment: 31.9% of patients with the T/T genotype presented a complete or a partial response versus no patients with T/G or G/G genotypes P=0.004;A let 7 microRNA SNP in the KRAS 3'UTR is prognostic in early stage colorectal cancer; Recently a SNP in a lethal-7 let-7 miRNA complementary site LCS6 in the KRAS 3'untranslated region was suggested to affect survival in metastatic CRC;Let 7 miRNA binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5 fluorouracil and oxaliplatin +/ cetuximab; Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site LCS6 within the 3'untranslated region 3'UTR of KRAS rs61764370 and clinical outcome in metastatic colorectal cancer mCRC patients receiving cetuximab;A let 7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population; The let-7 microRNAs play a key role in regulating KRAS expression and a polymorphism in 3' untranslated region rs61764370 T/G of KRAS leads to its higher expression;Genetic modulation of the Let 7 microRNA binding to KRAS 3' untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab irinotecan; There is increasing evidence that the Let-7 microRNA miRNA exerts an effect as a tumor suppressor by targeting the KRAS mRNA; The Let-7 complementary site LCS6 T>G variant in the KRAS 3'-untranslated region weakens Let-7 binding;A let 7 microRNA binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy;High let 7a microRNA levels in KRAS mutated colorectal carcinomas may rescue anti EGFR therapy effects in patients with chemotherapy refractory metastatic disease; Preclinical and experimental data in vivo indicate that Lethal-7 Let-7 microRNA downregulates KRAS with antitumor effects in the presence of activating KRAS mutations; In 59 patients harboring KRAS mutations Let-7a levels were analyzed for association with overall survival OS and progression-free survival PFS times; An exploratory subgroup analysis was performed using the rs61764370 LCS6 T>G polymorphism that experimentally impairs Let-7 binding to KRAS mRNA; In patients with KRAS mutations Let-7a analysis may serve to identify subgroups of patients who may still benefit from EGFR inhibition and this may open up new perspectives for alternative treatment strategies;A SNP in a let 7 microRNA complementary site in the KRAS 3' untranslated region increases non small cell lung cancer risk; The purpose of this study was to identify single nucleotide polymorphisms SNP that could modify let-7 binding and to assess the effect of such SNPs on target gene regulation and risk for non-small cell lung cancer NSCLC let-7 complementary sites LCS were sequenced in the KRAS 3' untranslated region from 74 NSCLC cases to identify mutations and SNPs that correlated with NSCLC; The LCS6 variant allele in a KRAS miRANA complementary site is significantly associated with increased risk for NSCLC among moderate smokers and represents a new paradigm for let-7 miRNAs in lung cancer susceptibility |
| 30 | hsa-let-7b-3p | KRAS | -1.82 | 0 | 0.54 | 0.00142 | mirMAP; miRNATAP | -0.21 | 0 | 24727325; 20603437; 24890702; 23324806; 21994416; 23167843; 27620744; 20177422; 25183481; 26581910; 22584434; 26516699; 18922928 | Association study of the let 7 miRNA complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer NCCTG N0147 Clinical Trial; A let-7 microRNA-complementary site LCS6 polymorphism in the 3' untranslated region of the KRAS gene has been shown to disrupt let-7 binding and upregulate KRAS expression;A let 7 microRNA binding site polymorphism in 3' untranslated region of KRAS gene predicts response in wild type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy; A polymorphism in a let-7 microRNA complementary site lcs6 in the KRAS 3' untranslated region UTR is associated with an increased cancer risk in non-small-cell lung cancer and reduced overall survival OS in oral cancers; the presence of KRAS let-7 lcs6 polymorphism was evaluated in 130 mCRC patients who were enrolled in a phase II study of cetuximab monotherapy IMCL-0144; KRAS let-7 lcs6 polymorphism was found to be related to object response rate ORR in mCRC patients whose tumors had KRASwt;Let 7 microRNA binding site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta analysis; There is a small but growing body of literature regarding the predictive utility of a Let-7 microRNA-binding-site polymorphism in the 3'-untranslated region UTR of KRAS KRAS-LCS6 for colorectal cancer outcome although the results are conflicting; A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism LCS6; rs61764370 and colorectal cancer outcome;The LCS6 polymorphism in the binding site of let 7 microRNA to the KRAS 3' untranslated region: its role in the efficacy of anti EGFR based therapy in metastatic colorectal cancer patients; The lethal-7 let-7 family of microRNAs regulates KRAS activity; We studied the association of the KRAS let-7 LCS6 polymorphism with the response in 100 refractory mCRC patients treated with anti-EGFR antibodies; The KRAS let-7 LCS6 polymorphism was genotyped using the BioMark system in blood and tumor DNA samples; The KRAS let-7 LCS6 G-allele showed a statistically significant association with nonresponse to anti-EGFR-based treatment: 31.9% of patients with the T/T genotype presented a complete or a partial response versus no patients with T/G or G/G genotypes P=0.004;A let 7 microRNA SNP in the KRAS 3'UTR is prognostic in early stage colorectal cancer; Recently a SNP in a lethal-7 let-7 miRNA complementary site LCS6 in the KRAS 3'untranslated region was suggested to affect survival in metastatic CRC;Let 7 miRNA binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5 fluorouracil and oxaliplatin +/ cetuximab; Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site LCS6 within the 3'untranslated region 3'UTR of KRAS rs61764370 and clinical outcome in metastatic colorectal cancer mCRC patients receiving cetuximab;A let 7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population; The let-7 microRNAs play a key role in regulating KRAS expression and a polymorphism in 3' untranslated region rs61764370 T/G of KRAS leads to its higher expression;Genetic modulation of the Let 7 microRNA binding to KRAS 3' untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab irinotecan; There is increasing evidence that the Let-7 microRNA miRNA exerts an effect as a tumor suppressor by targeting the KRAS mRNA; The Let-7 complementary site LCS6 T>G variant in the KRAS 3'-untranslated region weakens Let-7 binding;A let 7 microRNA binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy;Our results showed that miR-143 but not let-7b increased sensitization of KRAS mutant tumor cells to paclitaxel; Furthermore transfection of miR-143 but not let-7b mimic negatively regulated the expression of mutant but not wild-type KRAS;Preclinical and experimental data in vivo indicate that Lethal-7 Let-7 microRNA downregulates KRAS with antitumor effects in the presence of activating KRAS mutations; An exploratory subgroup analysis was performed using the rs61764370 LCS6 T>G polymorphism that experimentally impairs Let-7 binding to KRAS mRNA;Interestingly the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression;A SNP in a let 7 microRNA complementary site in the KRAS 3' untranslated region increases non small cell lung cancer risk; The purpose of this study was to identify single nucleotide polymorphisms SNP that could modify let-7 binding and to assess the effect of such SNPs on target gene regulation and risk for non-small cell lung cancer NSCLC let-7 complementary sites LCS were sequenced in the KRAS 3' untranslated region from 74 NSCLC cases to identify mutations and SNPs that correlated with NSCLC; The LCS6 variant allele in a KRAS miRANA complementary site is significantly associated with increased risk for NSCLC among moderate smokers and represents a new paradigm for let-7 miRNAs in lung cancer susceptibility |
| 31 | hsa-miR-1-3p | KRAS | -1.48 | 0.00024 | 0.54 | 0.00142 | MirTarget | -0.11 | 0 | NA | |
| 32 | hsa-miR-126-3p | KRAS | 0.4 | 0.11564 | 0.54 | 0.00142 | miRNAWalker2 validate; miRTarBase | -0.14 | 0 | 22845403 | miR-126 is also known to target other crucial oncogenes in PDAC such as KRAS and CRK |
| 33 | hsa-miR-1271-5p | KRAS | -0.02 | 0.9511 | 0.54 | 0.00142 | MirTarget | -0.11 | 7.0E-5 | NA | |
| 34 | hsa-miR-140-3p | KRAS | -1.11 | 0 | 0.54 | 0.00142 | MirTarget | -0.38 | 0 | NA | |
| 35 | hsa-miR-155-5p | KRAS | 0.81 | 0.00061 | 0.54 | 0.00142 | miRNAWalker2 validate; miRNATAP | -0.14 | 3.0E-5 | NA | |
| 36 | hsa-miR-16-1-3p | KRAS | 1.5 | 0 | 0.54 | 0.00142 | mirMAP | -0.12 | 0.00206 | NA | |
| 37 | hsa-miR-181a-5p | KRAS | -0.38 | 0.05621 | 0.54 | 0.00142 | miRNAWalker2 validate | -0.23 | 0 | 24098024; 27517749; 26124189 | The KRAS mutational status was determined by pyrosequencing and miR-181a expression was measured by quantitative RT-PCR in CRC tumour tissue and corresponding non-neoplastic colon tissue;Here we report that miR-181a directly binds to 3'-untranslated regions UTRs; downregulates KRAS NRAS and MAPK1; and decreases AML growth; The delivery of miR-181a mimics to target AML cells using transferrin-targeting lipopolyplex nanoparticles NP increased mature miR-181a; downregulated KRAS NRAS and MAPK1; and resulted in decreased phosphorylation of the downstream RAS effectors;MiR 181a 5p inhibits cell proliferation and migration by targeting Kras in non small cell lung cancer A549 cells; Luciferase activity assay results demonstrated that two binding sites of Kras could be directly targeted by miR-181a-5p; Furthermore Kras was down-regulated by miR-181a-5p at both transcriptional and translational levels; SiRNA-mediated Kras down-regulation could mimic the effects of miR-181a-5p mimic in A549 cells; Our findings suggest that miR-181a-5p plays a potential role in tumor suppression by partially targeting Kras and has the potential therapeutic application in NSCLC patients |
| 38 | hsa-miR-181c-5p | KRAS | 0.53 | 0.01259 | 0.54 | 0.00142 | miRNAWalker2 validate; miRTarBase | -0.11 | 0.002 | NA | |
| 39 | hsa-miR-186-5p | KRAS | 0.85 | 0 | 0.54 | 0.00142 | mirMAP | -0.17 | 0.00201 | NA | |
| 40 | hsa-miR-193a-3p | KRAS | 0.55 | 0.0319 | 0.54 | 0.00142 | MirTarget; miRanda; miRNATAP | -0.11 | 0.00055 | NA | |
| 41 | hsa-miR-193a-5p | KRAS | -1.16 | 0 | 0.54 | 0.00142 | miRNATAP | -0.14 | 0.00022 | NA | |
| 42 | hsa-miR-195-3p | KRAS | -1.33 | 0 | 0.54 | 0.00142 | mirMAP | -0.26 | 0 | NA | |
| 43 | hsa-miR-199a-5p | KRAS | 1.31 | 0 | 0.54 | 0.00142 | miRanda; miRNATAP | -0.19 | 0 | NA | |
| 44 | hsa-miR-199b-5p | KRAS | 2.14 | 0 | 0.54 | 0.00142 | miRanda; miRNATAP | -0.16 | 0 | 27517624 | The miR-199b prognostic impact was particularly evident in both younger and KRAS wild-type subgroups |
| 45 | hsa-miR-224-3p | KRAS | 0.92 | 0.01001 | 0.54 | 0.00142 | mirMAP | -0.12 | 0 | 25919696 | MicroRNA 224 is associated with colorectal cancer progression and response to 5 fluorouracil based chemotherapy by KRAS dependent and independent mechanisms; MicroRNA-224 was differentially expressed in dysplastic colorectal disease and in isogeneic KRAS WT and mutant HCT116 cells; 5-FU chemosensitivity was significantly increased in miR-224 knockdown cells and in NIH3T3 cells expressing KRAS and BRAF mutant proteins |
| 46 | hsa-miR-27b-3p | KRAS | 0.24 | 0.12264 | 0.54 | 0.00142 | miRNATAP | -0.14 | 0.00626 | NA | |
| 47 | hsa-miR-30a-3p | KRAS | -2.54 | 0 | 0.54 | 0.00142 | MirTarget; miRNATAP | -0.12 | 0 | NA | |
| 48 | hsa-miR-30a-5p | KRAS | -0.92 | 0.00076 | 0.54 | 0.00142 | mirMAP; miRNATAP | -0.16 | 0 | NA | |
| 49 | hsa-miR-30b-5p | KRAS | 0.36 | 0.13803 | 0.54 | 0.00142 | mirMAP; miRNATAP | -0.15 | 0 | NA | |
| 50 | hsa-miR-30c-5p | KRAS | -0.33 | 0.1236 | 0.54 | 0.00142 | mirMAP; miRNATAP | -0.3 | 0 | 22701724 | Deregulated miRNAs in hereditary breast cancer revealed a role for miR 30c in regulating KRAS oncogene; In particular we experimentally validated KRAS as a miR-30c target; Luciferase assays confirmed that miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein; In addition we provide evidence that KRAS is a target of miR-30c and that this miRNA suppresses breast cancer cell growth potentially through inhibition of KRAS signaling |
| 51 | hsa-miR-30d-3p | KRAS | 0 | 0.98646 | 0.54 | 0.00142 | MirTarget; miRNATAP | -0.12 | 0.00128 | NA | |
| 52 | hsa-miR-30d-5p | KRAS | -0.92 | 4.0E-5 | 0.54 | 0.00142 | mirMAP; miRNATAP | -0.12 | 0.00036 | NA | |
| 53 | hsa-miR-30e-3p | KRAS | -0.1 | 0.52624 | 0.54 | 0.00142 | MirTarget | -0.25 | 0 | NA | |
| 54 | hsa-miR-30e-5p | KRAS | 1.6 | 0 | 0.54 | 0.00142 | mirMAP; miRNATAP | -0.13 | 0.00268 | NA | |
| 55 | hsa-miR-501-3p | KRAS | -0.04 | 0.8668 | 0.54 | 0.00142 | MirTarget; PITA; TargetScan; miRNATAP | -0.12 | 0.00011 | NA | |
| 56 | hsa-miR-502-3p | KRAS | -0.26 | 0.16176 | 0.54 | 0.00142 | MirTarget; PITA; miRNATAP | -0.12 | 0.00538 | NA | |
| 57 | hsa-miR-532-5p | KRAS | 0.58 | 0.00232 | 0.54 | 0.00142 | MirTarget; PITA; miRNATAP | -0.12 | 0.00273 | NA | |
| 58 | hsa-miR-30c-5p | MAP2K1 | -0.33 | 0.1236 | -0.13 | 0.25581 | miRNAWalker2 validate | -0.15 | 0 | NA | |
| 59 | hsa-miR-497-5p | MAP2K1 | -0.05 | 0.78621 | -0.13 | 0.25581 | miRNAWalker2 validate | -0.15 | 0 | NA | |
| 60 | hsa-miR-130a-3p | MAPK1 | 0.88 | 0.00016 | -0.31 | 0.00657 | mirMAP | -0.1 | 1.0E-5 | NA | |
| 61 | hsa-miR-140-5p | MAPK1 | 0.67 | 0.00034 | -0.31 | 0.00657 | miRanda | -0.11 | 0.0003 | NA | |
| 62 | hsa-miR-148a-3p | MAPK1 | 2.31 | 0 | -0.31 | 0.00657 | mirMAP | -0.1 | 0 | NA | |
| 63 | hsa-miR-24-1-5p | MAPK1 | 0.86 | 0.00011 | -0.31 | 0.00657 | mirMAP | -0.11 | 1.0E-5 | NA | |
| 64 | hsa-miR-29a-5p | MAPK1 | 1.9 | 0 | -0.31 | 0.00657 | mirMAP | -0.1 | 1.0E-5 | NA | |
| 65 | hsa-miR-29b-3p | MAPK1 | 3.11 | 0 | -0.31 | 0.00657 | mirMAP | -0.12 | 0 | NA | |
| 66 | hsa-miR-342-3p | MAPK1 | -0.13 | 0.56103 | -0.31 | 0.00657 | miRanda; mirMAP | -0.14 | 0 | NA | |
| 67 | hsa-miR-34a-5p | MAPK1 | 1.41 | 0 | -0.31 | 0.00657 | mirMAP | -0.11 | 3.0E-5 | NA | |
| 68 | hsa-miR-454-3p | MAPK1 | 1.49 | 0 | -0.31 | 0.00657 | mirMAP | -0.1 | 2.0E-5 | NA | |
| 69 | hsa-miR-128-3p | MAPKAPK3 | 1.04 | 0 | -0.35 | 0.02552 | MirTarget | -0.21 | 0 | NA | |
| 70 | hsa-miR-421 | MAPKAPK3 | 0.17 | 0.53528 | -0.35 | 0.02552 | miRanda | -0.11 | 0.0002 | NA | |
| 71 | hsa-miR-130b-5p | NFAT5 | 1.54 | 0 | -0.41 | 0.00242 | MirTarget; miRNATAP | -0.11 | 0 | NA | |
| 72 | hsa-miR-132-3p | NFAT5 | 0.01 | 0.93403 | -0.41 | 0.00242 | miRNATAP | -0.13 | 0.00234 | NA | |
| 73 | hsa-miR-148b-3p | NFAT5 | 0.48 | 0.00265 | -0.41 | 0.00242 | miRNATAP | -0.11 | 0.00381 | NA | |
| 74 | hsa-miR-27b-5p | NFAT5 | 1.04 | 0 | -0.41 | 0.00242 | miRNATAP | -0.16 | 3.0E-5 | NA | |
| 75 | hsa-miR-590-3p | NFAT5 | 0.84 | 0.00129 | -0.41 | 0.00242 | MirTarget; miRanda; mirMAP; miRNATAP | -0.12 | 5.0E-5 | NA | |
| 76 | hsa-miR-590-5p | NFAT5 | 2.07 | 0 | -0.41 | 0.00242 | PITA; mirMAP; miRNATAP | -0.13 | 0 | NA | |
| 77 | hsa-miR-93-5p | NFAT5 | 1.51 | 0 | -0.41 | 0.00242 | MirTarget; miRNATAP | -0.12 | 3.0E-5 | NA | |
| 78 | hsa-miR-3127-5p | NFATC1 | 0.38 | 0.11536 | -1.14 | 0 | MirTarget | -0.11 | 0.00286 | NA | |
| 79 | hsa-miR-421 | NFATC1 | 0.17 | 0.53528 | -1.14 | 0 | miRanda | -0.27 | 0 | NA | |
| 80 | hsa-miR-130b-5p | NFATC2 | 1.54 | 0 | -1.18 | 0.0004 | MirTarget | -0.17 | 0.00222 | NA | |
| 81 | hsa-miR-182-5p | NFATC2 | 3.22 | 0 | -1.18 | 0.0004 | mirMAP | -0.18 | 0.0017 | NA | |
| 82 | hsa-miR-185-5p | NFATC2 | 1.14 | 0 | -1.18 | 0.0004 | MirTarget | -0.36 | 0.00019 | NA | |
| 83 | hsa-miR-186-5p | NFATC2 | 0.85 | 0 | -1.18 | 0.0004 | mirMAP | -0.34 | 0.00202 | NA | |
| 84 | hsa-miR-19a-3p | NFATC2 | 2.12 | 0 | -1.18 | 0.0004 | mirMAP | -0.34 | 0 | NA | |
| 85 | hsa-miR-19b-3p | NFATC2 | 2.11 | 0 | -1.18 | 0.0004 | mirMAP | -0.38 | 0 | NA | |
| 86 | hsa-miR-2355-3p | NFATC2 | 1.11 | 1.0E-5 | -1.18 | 0.0004 | mirMAP | -0.22 | 0.00088 | NA | |
| 87 | hsa-miR-29a-5p | NFATC2 | 1.9 | 0 | -1.18 | 0.0004 | mirMAP; miRNATAP | -0.18 | 0.00606 | NA | |
| 88 | hsa-miR-30b-5p | NFATC2 | 0.36 | 0.13803 | -1.18 | 0.0004 | MirTarget; mirMAP | -0.2 | 0.00171 | NA | |
| 89 | hsa-miR-3613-5p | NFATC2 | 0.02 | 0.93473 | -1.18 | 0.0004 | mirMAP | -0.24 | 0.00013 | NA | |
| 90 | hsa-miR-590-3p | NFATC2 | 0.84 | 0.00129 | -1.18 | 0.0004 | mirMAP | -0.26 | 0.00018 | NA | |
| 91 | hsa-miR-9-5p | NFATC2 | 4.99 | 0 | -1.18 | 0.0004 | MirTarget | -0.11 | 6.0E-5 | NA | |
| 92 | hsa-miR-15a-5p | NFATC3 | 1.63 | 0 | -0.78 | 0 | MirTarget; miRNATAP | -0.19 | 0 | NA | |
| 93 | hsa-miR-185-5p | NFATC3 | 1.14 | 0 | -0.78 | 0 | MirTarget; miRNATAP | -0.24 | 0 | NA | |
| 94 | hsa-miR-21-3p | NFATC3 | 2.54 | 0 | -0.78 | 0 | MirTarget | -0.14 | 0 | NA | |
| 95 | hsa-miR-29b-3p | NFATC3 | 3.11 | 0 | -0.78 | 0 | MirTarget; miRNATAP | -0.11 | 0 | NA | |
| 96 | hsa-miR-335-3p | NFATC3 | 1.51 | 0 | -0.78 | 0 | mirMAP | -0.1 | 0.00019 | NA | |
| 97 | hsa-miR-589-3p | NFATC3 | 1.34 | 2.0E-5 | -0.78 | 0 | mirMAP | -0.12 | 0 | NA | |
| 98 | hsa-miR-590-3p | NFATC3 | 0.84 | 0.00129 | -0.78 | 0 | miRanda | -0.14 | 0 | NA | |
| 99 | hsa-miR-185-3p | NFATC4 | -0.38 | 0.09365 | 0.94 | 3.0E-5 | MirTarget | -0.15 | 0.00074 | NA | |
| 100 | hsa-miR-423-5p | NFATC4 | -1.8 | 0 | 0.94 | 3.0E-5 | miRNATAP | -0.21 | 2.0E-5 | NA | |
| 101 | hsa-miR-145-5p | NRAS | -1.35 | 0 | 0.11 | 0.41292 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.14 | 0 | 26973415 | miR-145 expression was significantly downregulated in colon cancer tissues with its expression in normal colonic tissues being 4-5-fold higher two sample t test P < 0.05 whereas N-ras expression showed the opposite trend |
| 102 | hsa-miR-148a-3p | NRAS | 2.31 | 0 | 0.11 | 0.41292 | MirTarget | -0.11 | 1.0E-5 | NA | |
| 103 | hsa-miR-195-3p | NRAS | -1.33 | 0 | 0.11 | 0.41292 | mirMAP | -0.16 | 0 | NA | |
| 104 | hsa-miR-22-3p | NRAS | 1.43 | 0 | 0.11 | 0.41292 | MirTarget; miRNATAP | -0.13 | 0.00314 | NA | |
| 105 | hsa-miR-26b-5p | NRAS | 0.72 | 5.0E-5 | 0.11 | 0.41292 | mirMAP; miRNATAP | -0.13 | 0.00019 | NA | |
| 106 | hsa-miR-27b-3p | NRAS | 0.24 | 0.12264 | 0.11 | 0.41292 | miRNATAP | -0.15 | 0.00016 | NA | |
| 107 | hsa-miR-29a-3p | NRAS | 0.1 | 0.5732 | 0.11 | 0.41292 | miRNATAP | -0.16 | 1.0E-5 | NA | |
| 108 | hsa-miR-29b-3p | NRAS | 3.11 | 0 | 0.11 | 0.41292 | miRNATAP | -0.13 | 0 | NA | |
| 109 | hsa-miR-29c-3p | NRAS | 1.32 | 0 | 0.11 | 0.41292 | miRNATAP | -0.13 | 0 | NA | |
| 110 | hsa-miR-320a | NRAS | -0.96 | 0 | 0.11 | 0.41292 | mirMAP | -0.14 | 0.00012 | NA | |
| 111 | hsa-miR-502-3p | NRAS | -0.26 | 0.16176 | 0.11 | 0.41292 | MirTarget | -0.12 | 0.00049 | NA | |
| 112 | hsa-miR-664a-3p | NRAS | 0.44 | 0.02142 | 0.11 | 0.41292 | MirTarget | -0.34 | 0 | NA | |
| 113 | hsa-miR-186-5p | PIK3CA | 0.85 | 0 | -0.34 | 0.01077 | mirMAP | -0.16 | 0.00027 | NA | |
| 114 | hsa-miR-501-5p | PIK3CA | 0.41 | 0.10435 | -0.34 | 0.01077 | mirMAP | -0.12 | 0 | NA | |
| 115 | hsa-miR-96-5p | PIK3CA | 3.04 | 0 | -0.34 | 0.01077 | TargetScan | -0.13 | 0 | NA | |
| 116 | hsa-miR-454-3p | PIK3CB | 1.49 | 0 | 0.05 | 0.7085 | miRNATAP | -0.11 | 0.00028 | NA | |
| 117 | hsa-miR-421 | PIK3CD | 0.17 | 0.53528 | -0.17 | 0.40082 | miRanda | -0.19 | 0 | NA | |
| 118 | hsa-miR-148b-3p | PIK3CG | 0.48 | 0.00265 | -1.19 | 5.0E-5 | miRNAWalker2 validate | -0.24 | 0.00515 | NA | |
| 119 | hsa-miR-26b-5p | PIK3CG | 0.72 | 5.0E-5 | -1.19 | 5.0E-5 | miRNAWalker2 validate | -0.29 | 0.0002 | NA | |
| 120 | hsa-miR-29b-3p | PIK3CG | 3.11 | 0 | -1.19 | 5.0E-5 | miRTarBase | -0.13 | 0.00564 | NA | |
| 121 | hsa-miR-335-3p | PIK3CG | 1.51 | 0 | -1.19 | 5.0E-5 | mirMAP | -0.27 | 2.0E-5 | NA | |
| 122 | hsa-miR-542-3p | PIK3CG | 1.62 | 0 | -1.19 | 5.0E-5 | miRanda | -0.19 | 0.00032 | NA | |
| 123 | hsa-miR-106a-5p | PIK3R1 | 1.39 | 6.0E-5 | -1.29 | 0 | MirTarget; miRNATAP | -0.15 | 0 | NA | |
| 124 | hsa-miR-106b-5p | PIK3R1 | 1.47 | 0 | -1.29 | 0 | MirTarget; miRNATAP | -0.27 | 0 | NA | |
| 125 | hsa-miR-128-3p | PIK3R1 | 1.04 | 0 | -1.29 | 0 | MirTarget | -0.26 | 0 | 25962360 | miR 128 3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients; Mechanistically miR-128-3p was confirmed to regulate PIK3R1 p85α expression thereby suppressing phosphatidylinositol 3-kinase PI3K/AKT pathway activation using qRT-PCR and western blot analysis; Hence we conclude that miR-128-3p which is frequently downregulated in HCC inhibits HCC progression by regulating PIK3R1 and PI3K/AKT activation and is a prognostic marker for HCC patients |
| 126 | hsa-miR-1301-3p | PIK3R1 | 0.85 | 0.00058 | -1.29 | 0 | MirTarget | -0.25 | 0 | NA | |
| 127 | hsa-miR-15a-5p | PIK3R1 | 1.63 | 0 | -1.29 | 0 | MirTarget | -0.2 | 0 | NA | |
| 128 | hsa-miR-16-2-3p | PIK3R1 | 0.5 | 0.02636 | -1.29 | 0 | MirTarget | -0.22 | 0 | NA | |
| 129 | hsa-miR-16-5p | PIK3R1 | 0.75 | 0 | -1.29 | 0 | MirTarget | -0.15 | 0.00246 | NA | |
| 130 | hsa-miR-17-5p | PIK3R1 | 2.07 | 0 | -1.29 | 0 | MirTarget; TargetScan; miRNATAP | -0.31 | 0 | NA | |
| 131 | hsa-miR-182-5p | PIK3R1 | 3.22 | 0 | -1.29 | 0 | miRNATAP | -0.15 | 0 | NA | |
| 132 | hsa-miR-185-5p | PIK3R1 | 1.14 | 0 | -1.29 | 0 | miRNATAP | -0.27 | 0 | NA | |
| 133 | hsa-miR-186-5p | PIK3R1 | 0.85 | 0 | -1.29 | 0 | mirMAP | -0.27 | 0 | NA | |
| 134 | hsa-miR-200c-3p | PIK3R1 | 0.38 | 0.08422 | -1.29 | 0 | mirMAP | -0.17 | 0 | NA | |
| 135 | hsa-miR-20a-5p | PIK3R1 | 2.65 | 0 | -1.29 | 0 | MirTarget; miRNATAP | -0.27 | 0 | NA | |
| 136 | hsa-miR-21-5p | PIK3R1 | 4.38 | 0 | -1.29 | 0 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.24 | 0 | 26676464 | PIK3R1 targeting by miR 21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT and predicts clinical outcome of breast cancer; Next we identified the PIK3R1 as a direct target of miR-21 and showed that it was negatively regulated by miR-21; Taken together we provide novel evidence that miR-21 knockdown suppresses cell growth migration and invasion partly by inhibiting PI3K/AKT activation via direct targeting PIK3R1 and reversing EMT in breast cancer |
| 137 | hsa-miR-22-5p | PIK3R1 | 1.71 | 0 | -1.29 | 0 | mirMAP | -0.25 | 0 | NA | |
| 138 | hsa-miR-29b-3p | PIK3R1 | 3.11 | 0 | -1.29 | 0 | MirTarget; miRNATAP | -0.17 | 0 | NA | |
| 139 | hsa-miR-335-3p | PIK3R1 | 1.51 | 0 | -1.29 | 0 | mirMAP | -0.17 | 0 | NA | |
| 140 | hsa-miR-424-5p | PIK3R1 | 1.26 | 1.0E-5 | -1.29 | 0 | MirTarget | -0.12 | 1.0E-5 | NA | |
| 141 | hsa-miR-450b-5p | PIK3R1 | 1.69 | 0 | -1.29 | 0 | miRNATAP | -0.11 | 8.0E-5 | NA | |
| 142 | hsa-miR-582-5p | PIK3R1 | 1.08 | 0.00149 | -1.29 | 0 | mirMAP | -0.12 | 0 | NA | |
| 143 | hsa-miR-589-3p | PIK3R1 | 1.34 | 2.0E-5 | -1.29 | 0 | mirMAP | -0.11 | 2.0E-5 | NA | |
| 144 | hsa-miR-590-3p | PIK3R1 | 0.84 | 0.00129 | -1.29 | 0 | miRanda; mirMAP | -0.21 | 0 | NA | |
| 145 | hsa-miR-590-5p | PIK3R1 | 2.07 | 0 | -1.29 | 0 | MirTarget; PITA; miRanda; miRNATAP | -0.3 | 0 | NA | |
| 146 | hsa-miR-629-3p | PIK3R1 | 1.32 | 0.00011 | -1.29 | 0 | MirTarget | -0.16 | 0 | NA | |
| 147 | hsa-miR-93-5p | PIK3R1 | 1.51 | 0 | -1.29 | 0 | MirTarget; miRNATAP | -0.3 | 0 | NA | |
| 148 | hsa-miR-96-5p | PIK3R1 | 3.04 | 0 | -1.29 | 0 | TargetScan; miRNATAP | -0.25 | 0 | NA | |
| 149 | hsa-miR-29b-1-5p | PIK3R3 | 1.71 | 0 | -0.99 | 0 | mirMAP | -0.14 | 2.0E-5 | NA | |
| 150 | hsa-miR-335-3p | PIK3R3 | 1.51 | 0 | -0.99 | 0 | mirMAP | -0.24 | 0 | NA |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 35 | 1929 | 9.811e-27 | 4.565e-23 |
| 2 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 34 | 1977 | 6.167e-25 | 1.435e-21 |
| 3 | INTRACELLULAR SIGNAL TRANSDUCTION | 31 | 1572 | 6.949e-24 | 1.078e-20 |
| 4 | FC RECEPTOR SIGNALING PATHWAY | 17 | 206 | 1.139e-22 | 1.325e-19 |
| 5 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 19 | 323 | 1.487e-22 | 1.384e-19 |
| 6 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 14 | 142 | 8.485e-20 | 6.58e-17 |
| 7 | REGULATION OF IMMUNE RESPONSE | 22 | 858 | 1.873e-18 | 1.245e-15 |
| 8 | POSITIVE REGULATION OF CELL COMMUNICATION | 26 | 1532 | 9.974e-18 | 5.801e-15 |
| 9 | REGULATION OF IMMUNE SYSTEM PROCESS | 25 | 1403 | 1.905e-17 | 9.847e-15 |
| 10 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 26 | 1656 | 6.74e-17 | 3.136e-14 |
| 11 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 15 | 297 | 8.951e-17 | 3.786e-14 |
| 12 | PHOSPHATIDYLETHANOLAMINE ACYL CHAIN REMODELING | 8 | 23 | 1.967e-16 | 7.628e-14 |
| 13 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 13 | 193 | 3.224e-16 | 1.076e-13 |
| 14 | PLATELET ACTIVATION | 12 | 142 | 3.237e-16 | 1.076e-13 |
| 15 | PHOSPHATIDYLCHOLINE ACYL CHAIN REMODELING | 8 | 26 | 6.237e-16 | 1.935e-13 |
| 16 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 10 | 74 | 9.365e-16 | 2.691e-13 |
| 17 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 13 | 211 | 1.036e-15 | 2.691e-13 |
| 18 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 20 | 876 | 1.041e-15 | 2.691e-13 |
| 19 | GLYCEROLIPID METABOLIC PROCESS | 15 | 356 | 1.32e-15 | 3.234e-13 |
| 20 | PHOSPHOLIPID METABOLIC PROCESS | 15 | 364 | 1.833e-15 | 4.265e-13 |
| 21 | PHOSPHORYLATION | 22 | 1228 | 3.469e-15 | 7.687e-13 |
| 22 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 13 | 235 | 4.212e-15 | 8.908e-13 |
| 23 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 16 | 498 | 8.577e-15 | 1.735e-12 |
| 24 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 19 | 867 | 1.434e-14 | 2.78e-12 |
| 25 | ACTIVATION OF IMMUNE RESPONSE | 15 | 427 | 1.913e-14 | 3.56e-12 |
| 26 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 20 | 1036 | 2.508e-14 | 4.323e-12 |
| 27 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 20 | 1036 | 2.508e-14 | 4.323e-12 |
| 28 | POSITIVE REGULATION OF IMMUNE RESPONSE | 16 | 563 | 5.719e-14 | 9.504e-12 |
| 29 | CELL ACTIVATION | 16 | 568 | 6.553e-14 | 1.027e-11 |
| 30 | PROTEIN PHOSPHORYLATION | 19 | 944 | 6.623e-14 | 1.027e-11 |
| 31 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 24 | 1805 | 8.189e-14 | 1.229e-11 |
| 32 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 23 | 1618 | 8.74e-14 | 1.271e-11 |
| 33 | LOCOMOTION | 20 | 1114 | 9.805e-14 | 1.383e-11 |
| 34 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 20 | 1135 | 1.39e-13 | 1.903e-11 |
| 35 | ERBB SIGNALING PATHWAY | 9 | 79 | 1.432e-13 | 1.904e-11 |
| 36 | POSITIVE REGULATION OF LOCOMOTION | 14 | 420 | 3.405e-13 | 4.4e-11 |
| 37 | EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 8 | 55 | 4.628e-13 | 5.667e-11 |
| 38 | LEUKOCYTE MIGRATION | 12 | 259 | 4.54e-13 | 5.667e-11 |
| 39 | REGULATION OF KINASE ACTIVITY | 17 | 776 | 5.245e-13 | 6.194e-11 |
| 40 | PHOSPHATIDYLGLYCEROL METABOLIC PROCESS | 7 | 31 | 5.325e-13 | 6.194e-11 |
| 41 | LIPID BIOSYNTHETIC PROCESS | 15 | 539 | 5.618e-13 | 6.375e-11 |
| 42 | PHOSPHATIDYLINOSITOL ACYL CHAIN REMODELING | 6 | 16 | 8.301e-13 | 9.197e-11 |
| 43 | REGULATION OF TRANSPORT | 23 | 1804 | 8.686e-13 | 9.399e-11 |
| 44 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 11 | 207 | 1.087e-12 | 1.149e-10 |
| 45 | PHOSPHATIDYLSERINE ACYL CHAIN REMODELING | 6 | 17 | 1.281e-12 | 1.268e-10 |
| 46 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 16 | 689 | 1.255e-12 | 1.268e-10 |
| 47 | PHOSPHATIDYLGLYCEROL ACYL CHAIN REMODELING | 6 | 17 | 1.281e-12 | 1.268e-10 |
| 48 | TAXIS | 14 | 464 | 1.312e-12 | 1.272e-10 |
| 49 | POSITIVE REGULATION OF MAPK CASCADE | 14 | 470 | 1.56e-12 | 1.481e-10 |
| 50 | PHOSPHATIDYLCHOLINE METABOLIC PROCESS | 8 | 64 | 1.657e-12 | 1.542e-10 |
| 51 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 6 | 18 | 1.918e-12 | 1.75e-10 |
| 52 | POSITIVE REGULATION OF KINASE ACTIVITY | 14 | 482 | 2.191e-12 | 1.96e-10 |
| 53 | REGULATION OF PROTEIN MODIFICATION PROCESS | 22 | 1710 | 2.947e-12 | 2.587e-10 |
| 54 | HEMOSTASIS | 12 | 311 | 3.924e-12 | 3.381e-10 |
| 55 | IMMUNE SYSTEM PROCESS | 23 | 1984 | 6.31e-12 | 5.338e-10 |
| 56 | CELLULAR LIPID METABOLIC PROCESS | 17 | 913 | 7.032e-12 | 5.843e-10 |
| 57 | REGULATION OF TRANSFERASE ACTIVITY | 17 | 946 | 1.233e-11 | 1.007e-09 |
| 58 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 13 | 450 | 1.652e-11 | 1.325e-09 |
| 59 | REGULATION OF CELL DEATH | 20 | 1472 | 1.681e-11 | 1.326e-09 |
| 60 | ETHANOLAMINE CONTAINING COMPOUND METABOLIC PROCESS | 8 | 85 | 1.739e-11 | 1.348e-09 |
| 61 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 20 | 1492 | 2.149e-11 | 1.639e-09 |
| 62 | CELL MOTILITY | 16 | 835 | 2.264e-11 | 1.672e-09 |
| 63 | LOCALIZATION OF CELL | 16 | 835 | 2.264e-11 | 1.672e-09 |
| 64 | CALCIUM MEDIATED SIGNALING | 8 | 90 | 2.777e-11 | 1.988e-09 |
| 65 | VASCULATURE DEVELOPMENT | 13 | 469 | 2.765e-11 | 1.988e-09 |
| 66 | REGULATION OF LIPID METABOLIC PROCESS | 11 | 282 | 3.105e-11 | 2.189e-09 |
| 67 | RESPONSE TO NITROGEN COMPOUND | 16 | 859 | 3.453e-11 | 2.398e-09 |
| 68 | POSITIVE REGULATION OF GENE EXPRESSION | 21 | 1733 | 3.645e-11 | 2.494e-09 |
| 69 | PHOSPHATIDYLSERINE METABOLIC PROCESS | 6 | 28 | 3.826e-11 | 2.58e-09 |
| 70 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 289 | 4.04e-11 | 2.685e-09 |
| 71 | FC GAMMA RECEPTOR SIGNALING PATHWAY | 8 | 95 | 4.317e-11 | 2.829e-09 |
| 72 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 14 | 616 | 5.772e-11 | 3.73e-09 |
| 73 | REGULATION OF BODY FLUID LEVELS | 13 | 506 | 7.091e-11 | 4.52e-09 |
| 74 | REGULATION OF MAP KINASE ACTIVITY | 11 | 319 | 1.161e-10 | 7.303e-09 |
| 75 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 18 | 1275 | 1.368e-10 | 8.484e-09 |
| 76 | REGULATION OF MAPK CASCADE | 14 | 660 | 1.432e-10 | 8.765e-09 |
| 77 | AMMONIUM ION METABOLIC PROCESS | 9 | 169 | 1.494e-10 | 9.028e-09 |
| 78 | ALDITOL PHOSPHATE METABOLIC PROCESS | 6 | 35 | 1.629e-10 | 9.715e-09 |
| 79 | REGULATION OF CELL SUBSTRATE ADHESION | 9 | 173 | 1.841e-10 | 1.084e-08 |
| 80 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 17 | 1152 | 2.683e-10 | 1.56e-08 |
| 81 | LIPID METABOLIC PROCESS | 17 | 1158 | 2.907e-10 | 1.67e-08 |
| 82 | ERBB2 SIGNALING PATHWAY | 6 | 39 | 3.251e-10 | 1.845e-08 |
| 83 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 6 | 40 | 3.818e-10 | 2.141e-08 |
| 84 | WOUND HEALING | 12 | 470 | 4.652e-10 | 2.577e-08 |
| 85 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 20 | 1791 | 5.681e-10 | 3.11e-08 |
| 86 | AMINE METABOLIC PROCESS | 8 | 131 | 5.78e-10 | 3.127e-08 |
| 87 | ORGANOPHOSPHATE METABOLIC PROCESS | 15 | 885 | 6.142e-10 | 3.285e-08 |
| 88 | IMMUNE EFFECTOR PROCESS | 12 | 486 | 6.808e-10 | 3.6e-08 |
| 89 | RESPONSE TO EXTERNAL STIMULUS | 20 | 1821 | 7.62e-10 | 3.984e-08 |
| 90 | REGULATION OF INTRACELLULAR TRANSPORT | 13 | 621 | 8.735e-10 | 4.516e-08 |
| 91 | REGULATION OF CELL ADHESION | 13 | 629 | 1.02e-09 | 5.217e-08 |
| 92 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 14 | 771 | 1.085e-09 | 5.489e-08 |
| 93 | REGULATION OF LIPID KINASE ACTIVITY | 6 | 48 | 1.204e-09 | 6.024e-08 |
| 94 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 12 | 514 | 1.285e-09 | 6.358e-08 |
| 95 | POSITIVE REGULATION OF TRANSPORT | 15 | 936 | 1.326e-09 | 6.497e-08 |
| 96 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 6 | 49 | 1.37e-09 | 6.571e-08 |
| 97 | REGULATION OF CELL MATRIX ADHESION | 7 | 90 | 1.368e-09 | 6.571e-08 |
| 98 | PEPTIDYL SERINE MODIFICATION | 8 | 148 | 1.529e-09 | 7.26e-08 |
| 99 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 14 | 799 | 1.72e-09 | 8.083e-08 |
| 100 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 51 | 1.758e-09 | 8.18e-08 |
| 101 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 2.641e-09 | 1.216e-07 |
| 102 | LIPID PHOSPHORYLATION | 7 | 99 | 2.684e-09 | 1.224e-07 |
| 103 | SECOND MESSENGER MEDIATED SIGNALING | 8 | 160 | 2.837e-09 | 1.281e-07 |
| 104 | RESPONSE TO WOUNDING | 12 | 563 | 3.582e-09 | 1.603e-07 |
| 105 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 17 | 1381 | 4.282e-09 | 1.88e-07 |
| 106 | LIPID CATABOLIC PROCESS | 9 | 247 | 4.275e-09 | 1.88e-07 |
| 107 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 12 | 573 | 4.363e-09 | 1.897e-07 |
| 108 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 6 | 61 | 5.328e-09 | 2.295e-07 |
| 109 | REGULATION OF VESICLE MEDIATED TRANSPORT | 11 | 462 | 5.714e-09 | 2.439e-07 |
| 110 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 470 | 6.826e-09 | 2.887e-07 |
| 111 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 10 | 360 | 7.224e-09 | 3.028e-07 |
| 112 | REGULATION OF CYTOPLASMIC TRANSPORT | 11 | 481 | 8.671e-09 | 3.602e-07 |
| 113 | RESPONSE TO ENDOGENOUS STIMULUS | 17 | 1450 | 8.912e-09 | 3.67e-07 |
| 114 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 10 | 370 | 9.377e-09 | 3.827e-07 |
| 115 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 7 | 120 | 1.035e-08 | 4.186e-07 |
| 116 | CELLULAR RESPONSE TO PEPTIDE | 9 | 274 | 1.055e-08 | 4.23e-07 |
| 117 | REGULATION OF RESPONSE TO STRESS | 17 | 1468 | 1.072e-08 | 4.263e-07 |
| 118 | PHAGOCYTOSIS | 8 | 190 | 1.097e-08 | 4.325e-07 |
| 119 | REGULATION OF CELLULAR LOCALIZATION | 16 | 1277 | 1.109e-08 | 4.337e-07 |
| 120 | PHOSPHATIDIC ACID METABOLIC PROCESS | 5 | 33 | 1.164e-08 | 4.512e-07 |
| 121 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 8 | 195 | 1.344e-08 | 5.168e-07 |
| 122 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 11 | 505 | 1.432e-08 | 5.463e-07 |
| 123 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 13 | 788 | 1.525e-08 | 5.723e-07 |
| 124 | CIRCULATORY SYSTEM DEVELOPMENT | 13 | 788 | 1.525e-08 | 5.723e-07 |
| 125 | REGULATION OF PROTEIN LOCALIZATION | 14 | 950 | 1.565e-08 | 5.778e-07 |
| 126 | ENDOCYTOSIS | 11 | 509 | 1.553e-08 | 5.778e-07 |
| 127 | POSITIVE REGULATION OF LIPID METABOLIC PROCESS | 7 | 128 | 1.622e-08 | 5.941e-07 |
| 128 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 17 | 1518 | 1.766e-08 | 6.42e-07 |
| 129 | ANGIOGENESIS | 9 | 293 | 1.884e-08 | 6.795e-07 |
| 130 | POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 9 | 296 | 2.057e-08 | 7.363e-07 |
| 131 | SINGLE ORGANISM BIOSYNTHETIC PROCESS | 16 | 1340 | 2.191e-08 | 7.783e-07 |
| 132 | POSITIVE REGULATION OF CELL PROLIFERATION | 13 | 814 | 2.239e-08 | 7.894e-07 |
| 133 | MODULATION OF SYNAPTIC TRANSMISSION | 9 | 301 | 2.377e-08 | 8.315e-07 |
| 134 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 7 | 138 | 2.732e-08 | 9.487e-07 |
| 135 | REGULATION OF ORGANELLE ORGANIZATION | 15 | 1178 | 2.959e-08 | 1.02e-06 |
| 136 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 14 | 1021 | 3.869e-08 | 1.324e-06 |
| 137 | NEGATIVE REGULATION OF CELL DEATH | 13 | 872 | 5.03e-08 | 1.709e-06 |
| 138 | VESICLE MEDIATED TRANSPORT | 15 | 1239 | 5.774e-08 | 1.947e-06 |
| 139 | ICOSANOID BIOSYNTHETIC PROCESS | 5 | 46 | 6.572e-08 | 2.184e-06 |
| 140 | FATTY ACID DERIVATIVE BIOSYNTHETIC PROCESS | 5 | 46 | 6.572e-08 | 2.184e-06 |
| 141 | RESPONSE TO HORMONE | 13 | 893 | 6.644e-08 | 2.192e-06 |
| 142 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 95 | 7.867e-08 | 2.578e-06 |
| 143 | ALCOHOL METABOLIC PROCESS | 9 | 348 | 8.239e-08 | 2.681e-06 |
| 144 | ICOSANOID METABOLIC PROCESS | 6 | 96 | 8.377e-08 | 2.688e-06 |
| 145 | FATTY ACID DERIVATIVE METABOLIC PROCESS | 6 | 96 | 8.377e-08 | 2.688e-06 |
| 146 | REGULATION OF ADHERENS JUNCTION ORGANIZATION | 5 | 50 | 1.009e-07 | 3.216e-06 |
| 147 | REGULATION OF CELL PROLIFERATION | 16 | 1496 | 1.019e-07 | 3.226e-06 |
| 148 | CELLULAR RESPONSE TO GROWTH HORMONE STIMULUS | 4 | 20 | 1.155e-07 | 3.631e-06 |
| 149 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 8 | 258 | 1.175e-07 | 3.67e-06 |
| 150 | TISSUE HOMEOSTASIS | 7 | 171 | 1.194e-07 | 3.703e-06 |
| 151 | BLOOD VESSEL MORPHOGENESIS | 9 | 364 | 1.208e-07 | 3.721e-06 |
| 152 | POSITIVE REGULATION OF PROTEIN IMPORT | 6 | 104 | 1.352e-07 | 4.14e-06 |
| 153 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 13 | 957 | 1.485e-07 | 4.515e-06 |
| 154 | HOMEOSTATIC PROCESS | 15 | 1337 | 1.566e-07 | 4.731e-06 |
| 155 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 8 | 272 | 1.761e-07 | 5.288e-06 |
| 156 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 23 | 2.1e-07 | 6.264e-06 |
| 157 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 8 | 279 | 2.138e-07 | 6.338e-06 |
| 158 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 8 | 282 | 2.32e-07 | 6.833e-06 |
| 159 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 5 | 59 | 2.348e-07 | 6.87e-06 |
| 160 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 13 | 1004 | 2.579e-07 | 7.5e-06 |
| 161 | RESPONSE TO PEPTIDE | 9 | 404 | 2.914e-07 | 8.421e-06 |
| 162 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 17 | 1848 | 3.125e-07 | 8.976e-06 |
| 163 | CYTOKINE PRODUCTION | 6 | 120 | 3.167e-07 | 9.041e-06 |
| 164 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 121 | 3.327e-07 | 9.439e-06 |
| 165 | CELL DEVELOPMENT | 15 | 1426 | 3.608e-07 | 1.017e-05 |
| 166 | INOSITOL LIPID MEDIATED SIGNALING | 6 | 124 | 3.845e-07 | 1.078e-05 |
| 167 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 10 | 552 | 3.942e-07 | 1.098e-05 |
| 168 | NEURON PROJECTION GUIDANCE | 7 | 205 | 4.092e-07 | 1.133e-05 |
| 169 | REGULATION OF CELL PROJECTION ORGANIZATION | 10 | 558 | 4.352e-07 | 1.198e-05 |
| 170 | REGULATION OF PROTEIN TARGETING | 8 | 307 | 4.423e-07 | 1.211e-05 |
| 171 | LIPID MODIFICATION | 7 | 210 | 4.815e-07 | 1.303e-05 |
| 172 | REGULATION OF CELL JUNCTION ASSEMBLY | 5 | 68 | 4.814e-07 | 1.303e-05 |
| 173 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 129 | 4.856e-07 | 1.306e-05 |
| 174 | POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 6 | 133 | 5.814e-07 | 1.555e-05 |
| 175 | RESPONSE TO GROWTH HORMONE | 4 | 30 | 6.423e-07 | 1.703e-05 |
| 176 | REGULATION OF CELL DIFFERENTIATION | 15 | 1492 | 6.443e-07 | 1.703e-05 |
| 177 | REGULATION OF SYNAPTIC PLASTICITY | 6 | 140 | 7.86e-07 | 2.066e-05 |
| 178 | REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 7 | 232 | 9.404e-07 | 2.458e-05 |
| 179 | CELLULAR RESPONSE TO INSULIN STIMULUS | 6 | 146 | 1.005e-06 | 2.598e-05 |
| 180 | T CELL RECEPTOR SIGNALING PATHWAY | 6 | 146 | 1.005e-06 | 2.598e-05 |
| 181 | ORGANIC HYDROXY COMPOUND METABOLIC PROCESS | 9 | 482 | 1.27e-06 | 3.264e-05 |
| 182 | POSITIVE REGULATION OF DEFENSE RESPONSE | 8 | 364 | 1.591e-06 | 4.066e-05 |
| 183 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 8 | 368 | 1.726e-06 | 4.388e-05 |
| 184 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 14 | 1395 | 1.742e-06 | 4.404e-05 |
| 185 | NEUROGENESIS | 14 | 1402 | 1.848e-06 | 4.64e-05 |
| 186 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 3 | 11 | 1.855e-06 | 4.64e-05 |
| 187 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 4 | 39 | 1.899e-06 | 4.725e-05 |
| 188 | POSITIVE REGULATION OF CELL ADHESION | 8 | 376 | 2.025e-06 | 5.012e-05 |
| 189 | REGULATION OF EPITHELIAL CELL MIGRATION | 6 | 166 | 2.125e-06 | 5.204e-05 |
| 190 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 9 | 513 | 2.121e-06 | 5.204e-05 |
| 191 | REGULATION OF CELL CELL ADHESION | 8 | 380 | 2.191e-06 | 5.337e-05 |
| 192 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 8 | 381 | 2.234e-06 | 5.414e-05 |
| 193 | PEPTIDYL AMINO ACID MODIFICATION | 11 | 841 | 2.355e-06 | 5.677e-05 |
| 194 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 12 | 2.469e-06 | 5.922e-05 |
| 195 | POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE | 6 | 172 | 2.611e-06 | 6.23e-05 |
| 196 | MYELOID LEUKOCYTE MEDIATED IMMUNITY | 4 | 43 | 2.83e-06 | 6.718e-05 |
| 197 | MYELOID LEUKOCYTE MIGRATION | 5 | 99 | 3.132e-06 | 7.398e-05 |
| 198 | NEURON PROJECTION MORPHOGENESIS | 8 | 402 | 3.324e-06 | 7.811e-05 |
| 199 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 8 | 404 | 3.448e-06 | 8.061e-05 |
| 200 | NEURON PROJECTION DEVELOPMENT | 9 | 545 | 3.478e-06 | 8.092e-05 |
| 201 | ANATOMICAL STRUCTURE HOMEOSTASIS | 7 | 285 | 3.688e-06 | 8.537e-05 |
| 202 | REGULATION OF PROTEIN IMPORT | 6 | 183 | 3.737e-06 | 8.607e-05 |
| 203 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 5 | 103 | 3.808e-06 | 8.728e-05 |
| 204 | CELLULAR RESPONSE TO HORMONE STIMULUS | 9 | 552 | 3.859e-06 | 8.759e-05 |
| 205 | REGULATION OF CELL MORPHOGENESIS | 9 | 552 | 3.859e-06 | 8.759e-05 |
| 206 | POSITIVE REGULATION OF DNA METABOLIC PROCESS | 6 | 185 | 3.978e-06 | 8.986e-05 |
| 207 | ARACHIDONIC ACID SECRETION | 3 | 14 | 4.072e-06 | 9.109e-05 |
| 208 | ARACHIDONATE TRANSPORT | 3 | 14 | 4.072e-06 | 9.109e-05 |
| 209 | CELL PROJECTION ORGANIZATION | 11 | 902 | 4.62e-06 | 0.0001028 |
| 210 | UNSATURATED FATTY ACID METABOLIC PROCESS | 5 | 109 | 5.03e-06 | 0.0001114 |
| 211 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 7 | 303 | 5.514e-06 | 0.0001216 |
| 212 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 11 | 926 | 5.936e-06 | 0.0001303 |
| 213 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 7 | 307 | 6.008e-06 | 0.0001312 |
| 214 | REGULATION OF ENDOTHELIAL CELL MIGRATION | 5 | 114 | 6.266e-06 | 0.0001356 |
| 215 | REGULATION OF EARLY ENDOSOME TO LATE ENDOSOME TRANSPORT | 3 | 16 | 6.244e-06 | 0.0001356 |
| 216 | LEUKOCYTE CHEMOTAXIS | 5 | 117 | 7.115e-06 | 0.0001527 |
| 217 | B CELL RECEPTOR SIGNALING PATHWAY | 4 | 54 | 7.119e-06 | 0.0001527 |
| 218 | RESPONSE TO INSULIN | 6 | 205 | 7.174e-06 | 0.0001531 |
| 219 | REGULATION OF HOMEOSTATIC PROCESS | 8 | 447 | 7.244e-06 | 0.0001532 |
| 220 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 12 | 1142 | 7.222e-06 | 0.0001532 |
| 221 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 3 | 17 | 7.57e-06 | 0.0001572 |
| 222 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 10 | 767 | 7.555e-06 | 0.0001572 |
| 223 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 17 | 7.57e-06 | 0.0001572 |
| 224 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 7.57e-06 | 0.0001572 |
| 225 | POSITIVE REGULATION OF CHEMOTAXIS | 5 | 120 | 8.052e-06 | 0.0001665 |
| 226 | SINGLE ORGANISM CATABOLIC PROCESS | 11 | 957 | 8.115e-06 | 0.0001671 |
| 227 | SINGLE ORGANISM CELL ADHESION | 8 | 459 | 8.787e-06 | 0.0001801 |
| 228 | ENDOTHELIAL CELL MIGRATION | 4 | 57 | 8.848e-06 | 0.0001806 |
| 229 | MAST CELL MEDIATED IMMUNITY | 3 | 18 | 9.069e-06 | 0.0001843 |
| 230 | UNSATURATED FATTY ACID BIOSYNTHETIC PROCESS | 4 | 58 | 9.487e-06 | 0.0001919 |
| 231 | POSITIVE REGULATION OF HOMEOSTATIC PROCESS | 6 | 216 | 9.669e-06 | 0.0001948 |
| 232 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 218 | 1.019e-05 | 0.0002044 |
| 233 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 220 | 1.073e-05 | 0.0002135 |
| 234 | CELLULAR MODIFIED AMINO ACID METABOLIC PROCESS | 6 | 220 | 1.073e-05 | 0.0002135 |
| 235 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 7 | 337 | 1.103e-05 | 0.0002184 |
| 236 | CELL PART MORPHOGENESIS | 9 | 633 | 1.163e-05 | 0.0002293 |
| 237 | REGULATION OF DNA METABOLIC PROCESS | 7 | 340 | 1.168e-05 | 0.0002293 |
| 238 | CELL DEATH | 11 | 1001 | 1.24e-05 | 0.0002424 |
| 239 | ICOSANOID TRANSPORT | 3 | 20 | 1.263e-05 | 0.0002449 |
| 240 | FATTY ACID DERIVATIVE TRANSPORT | 3 | 20 | 1.263e-05 | 0.0002449 |
| 241 | REGULATION OF CELL ACTIVATION | 8 | 484 | 1.291e-05 | 0.0002493 |
| 242 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 6 | 228 | 1.315e-05 | 0.0002529 |
| 243 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 11 | 1008 | 1.324e-05 | 0.0002535 |
| 244 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 14 | 1672 | 1.431e-05 | 0.000273 |
| 245 | MAST CELL ACTIVATION | 3 | 21 | 1.471e-05 | 0.000276 |
| 246 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 7 | 352 | 1.462e-05 | 0.000276 |
| 247 | POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION | 3 | 21 | 1.471e-05 | 0.000276 |
| 248 | BONE RESORPTION | 3 | 21 | 1.471e-05 | 0.000276 |
| 249 | REGULATION OF VASCULATURE DEVELOPMENT | 6 | 233 | 1.487e-05 | 0.0002779 |
| 250 | RESPONSE TO ABIOTIC STIMULUS | 11 | 1024 | 1.534e-05 | 0.0002844 |
| 251 | ACTIVATION OF MAPK ACTIVITY | 5 | 137 | 1.533e-05 | 0.0002844 |
| 252 | DEFENSE RESPONSE | 12 | 1231 | 1.543e-05 | 0.0002848 |
| 253 | PLACENTA DEVELOPMENT | 5 | 138 | 1.588e-05 | 0.0002921 |
| 254 | REGULATION OF ERK1 AND ERK2 CASCADE | 6 | 238 | 1.677e-05 | 0.0003072 |
| 255 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 4 | 67 | 1.688e-05 | 0.0003081 |
| 256 | NON CANONICAL WNT SIGNALING PATHWAY | 5 | 140 | 1.702e-05 | 0.0003094 |
| 257 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 7 | 365 | 1.847e-05 | 0.0003343 |
| 258 | LYSOSOME LOCALIZATION | 3 | 23 | 1.953e-05 | 0.0003521 |
| 259 | NEURON DEVELOPMENT | 9 | 687 | 2.228e-05 | 0.0003942 |
| 260 | REGULATION OF POSITIVE CHEMOTAXIS | 3 | 24 | 2.228e-05 | 0.0003942 |
| 261 | POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY | 3 | 24 | 2.228e-05 | 0.0003942 |
| 262 | REGULATION OF ANOIKIS | 3 | 24 | 2.228e-05 | 0.0003942 |
| 263 | POSITIVE REGULATION OF LAMELLIPODIUM ORGANIZATION | 3 | 24 | 2.228e-05 | 0.0003942 |
| 264 | NEURON DIFFERENTIATION | 10 | 874 | 2.347e-05 | 0.0004136 |
| 265 | TISSUE DEVELOPMENT | 13 | 1518 | 2.499e-05 | 0.0004388 |
| 266 | REGULATION OF PEPTIDE TRANSPORT | 6 | 256 | 2.53e-05 | 0.0004408 |
| 267 | POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 3 | 25 | 2.528e-05 | 0.0004408 |
| 268 | GRANULOCYTE MIGRATION | 4 | 75 | 2.641e-05 | 0.0004586 |
| 269 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 14 | 1784 | 2.976e-05 | 0.0005148 |
| 270 | CELLULAR COMPONENT MORPHOGENESIS | 10 | 900 | 3.016e-05 | 0.0005179 |
| 271 | RESPONSE TO CYTOKINE | 9 | 714 | 3.016e-05 | 0.0005179 |
| 272 | LYMPHOCYTE COSTIMULATION | 4 | 78 | 3.084e-05 | 0.0005257 |
| 273 | REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 4 | 78 | 3.084e-05 | 0.0005257 |
| 274 | RESPONSE TO LITHIUM ION | 3 | 27 | 3.204e-05 | 0.0005441 |
| 275 | REGULATION OF DNA REPLICATION | 5 | 161 | 3.335e-05 | 0.0005643 |
| 276 | REGULATION OF NEURON DIFFERENTIATION | 8 | 554 | 3.4e-05 | 0.0005725 |
| 277 | INSULIN RECEPTOR SIGNALING PATHWAY | 4 | 80 | 3.408e-05 | 0.0005725 |
| 278 | CELL CHEMOTAXIS | 5 | 162 | 3.436e-05 | 0.0005748 |
| 279 | CELLULAR RESPONSE TO STRESS | 13 | 1565 | 3.446e-05 | 0.0005748 |
| 280 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 10 | 917 | 3.537e-05 | 0.0005878 |
| 281 | POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 28 | 3.583e-05 | 0.0005912 |
| 282 | POSITIVE REGULATION OF PROTEIN KINASE B SIGNALING | 4 | 81 | 3.579e-05 | 0.0005912 |
| 283 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 7 | 406 | 3.647e-05 | 0.0005996 |
| 284 | REPRODUCTIVE SYSTEM DEVELOPMENT | 7 | 408 | 3.763e-05 | 0.0006165 |
| 285 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 5 | 167 | 3.973e-05 | 0.0006486 |
| 286 | REGULATION OF VACUOLAR TRANSPORT | 3 | 29 | 3.99e-05 | 0.0006491 |
| 287 | LEUKOCYTE ACTIVATION | 7 | 414 | 4.128e-05 | 0.0006673 |
| 288 | TISSUE MIGRATION | 4 | 84 | 4.13e-05 | 0.0006673 |
| 289 | EPHRIN RECEPTOR SIGNALING PATHWAY | 4 | 85 | 4.327e-05 | 0.0006967 |
| 290 | LEUKOCYTE DEGRANULATION | 3 | 30 | 4.426e-05 | 0.0007101 |
| 291 | POSITIVE REGULATION OF DNA REPLICATION | 4 | 86 | 4.53e-05 | 0.0007244 |
| 292 | IMMUNE SYSTEM DEVELOPMENT | 8 | 582 | 4.82e-05 | 0.0007681 |
| 293 | REGULATION OF DEFENSE RESPONSE | 9 | 759 | 4.858e-05 | 0.0007715 |
| 294 | HOMEOSTASIS OF NUMBER OF CELLS WITHIN A TISSUE | 3 | 31 | 4.892e-05 | 0.0007743 |
| 295 | HOMEOSTASIS OF NUMBER OF CELLS | 5 | 175 | 4.966e-05 | 0.0007833 |
| 296 | SECRETION | 8 | 588 | 5.181e-05 | 0.0008145 |
| 297 | POSITIVE REGULATION OF LIPID KINASE ACTIVITY | 3 | 32 | 5.39e-05 | 0.0008444 |
| 298 | FATTY ACID METABOLIC PROCESS | 6 | 296 | 5.688e-05 | 0.0008852 |
| 299 | REGULATION OF CHEMOTAXIS | 5 | 180 | 5.678e-05 | 0.0008852 |
| 300 | POSITIVE REGULATION OF FATTY ACID METABOLIC PROCESS | 3 | 33 | 5.919e-05 | 0.0009181 |
| 301 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 8 | 602 | 6.113e-05 | 0.000945 |
| 302 | POSITIVE REGULATION OF CELL DEATH | 8 | 605 | 6.33e-05 | 0.0009753 |
| 303 | BONE REMODELING | 3 | 35 | 7.078e-05 | 0.001087 |
| 304 | INFLAMMATORY RESPONSE | 7 | 454 | 7.383e-05 | 0.00113 |
| 305 | PROTEIN AUTOPHOSPHORYLATION | 5 | 192 | 7.708e-05 | 0.001176 |
| 306 | POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 4 | 99 | 7.858e-05 | 0.001195 |
| 307 | REGULATION OF GLUCOSE TRANSPORT | 4 | 100 | 8.172e-05 | 0.001239 |
| 308 | REGULATION OF MUSCLE SYSTEM PROCESS | 5 | 195 | 8.293e-05 | 0.001253 |
| 309 | REGULATION OF LAMELLIPODIUM ORGANIZATION | 3 | 37 | 8.376e-05 | 0.001261 |
| 310 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 9 | 823 | 9.062e-05 | 0.00136 |
| 311 | REGULATION OF ENDOCYTOSIS | 5 | 199 | 9.127e-05 | 0.001365 |
| 312 | BIOLOGICAL ADHESION | 10 | 1032 | 9.548e-05 | 0.001424 |
| 313 | REGULATION OF CELL ADHESION MEDIATED BY INTEGRIN | 3 | 39 | 9.82e-05 | 0.001441 |
| 314 | ASTROCYTE DIFFERENTIATION | 3 | 39 | 9.82e-05 | 0.001441 |
| 315 | RESPONSE TO GROWTH FACTOR | 7 | 475 | 9.792e-05 | 0.001441 |
| 316 | PEPTIDYL TYROSINE AUTOPHOSPHORYLATION | 3 | 39 | 9.82e-05 | 0.001441 |
| 317 | POSITIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 3 | 39 | 9.82e-05 | 0.001441 |
| 318 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 4 | 106 | 0.0001025 | 0.001496 |
| 319 | ACTIVATION OF INNATE IMMUNE RESPONSE | 5 | 204 | 0.0001026 | 0.001496 |
| 320 | POSITIVE REGULATION OF CELL MATRIX ADHESION | 3 | 40 | 0.000106 | 0.001541 |
| 321 | MYELOID CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 3 | 41 | 0.0001142 | 0.001655 |
| 322 | SMALL MOLECULE METABOLIC PROCESS | 13 | 1767 | 0.0001208 | 0.001745 |
| 323 | POSITIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 3 | 42 | 0.0001228 | 0.001757 |
| 324 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 3 | 42 | 0.0001228 | 0.001757 |
| 325 | LONG CHAIN FATTY ACID TRANSPORT | 3 | 42 | 0.0001228 | 0.001757 |
| 326 | LYMPHOCYTE ACTIVATION | 6 | 342 | 0.0001259 | 0.001797 |
| 327 | REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 3 | 43 | 0.0001317 | 0.001869 |
| 328 | CELL PROLIFERATION | 8 | 672 | 0.0001314 | 0.001869 |
| 329 | SYSTEM PROCESS | 13 | 1785 | 0.0001338 | 0.001893 |
| 330 | FATTY ACID BIOSYNTHETIC PROCESS | 4 | 114 | 0.0001358 | 0.001915 |
| 331 | REGULATION OF MITOCHONDRION ORGANIZATION | 5 | 218 | 0.00014 | 0.001968 |
| 332 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 9 | 872 | 0.0001406 | 0.001971 |
| 333 | CHEMICAL HOMEOSTASIS | 9 | 874 | 0.0001431 | 0.001999 |
| 334 | MAMMARY GLAND DEVELOPMENT | 4 | 117 | 0.0001502 | 0.002092 |
| 335 | LUNG MORPHOGENESIS | 3 | 45 | 0.000151 | 0.002097 |
| 336 | REGULATED EXOCYTOSIS | 5 | 224 | 0.0001589 | 0.002201 |
| 337 | PEPTIDYL THREONINE MODIFICATION | 3 | 46 | 0.0001613 | 0.002214 |
| 338 | INTRASPECIES INTERACTION BETWEEN ORGANISMS | 3 | 46 | 0.0001613 | 0.002214 |
| 339 | SOCIAL BEHAVIOR | 3 | 46 | 0.0001613 | 0.002214 |
| 340 | REGULATION OF PROTEIN KINASE B SIGNALING | 4 | 121 | 0.0001709 | 0.002339 |
| 341 | REGULATION OF SECRETION | 8 | 699 | 0.0001722 | 0.002349 |
| 342 | RESPONSE TO BACTERIUM | 7 | 528 | 0.0001883 | 0.002562 |
| 343 | HEAD DEVELOPMENT | 8 | 709 | 0.0001897 | 0.002573 |
| 344 | ARACHIDONIC ACID METABOLIC PROCESS | 3 | 50 | 0.0002069 | 0.00279 |
| 345 | MUSCLE CELL DIFFERENTIATION | 5 | 237 | 0.0002066 | 0.00279 |
| 346 | MUSCLE CELL DEVELOPMENT | 4 | 128 | 0.0002121 | 0.002853 |
| 347 | REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 3 | 51 | 0.0002195 | 0.002943 |
| 348 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 4 | 131 | 0.0002318 | 0.003099 |
| 349 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 4 | 132 | 0.0002386 | 0.003182 |
| 350 | MAMMARY GLAND EPITHELIUM DEVELOPMENT | 3 | 53 | 0.0002461 | 0.003262 |
| 351 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 5 | 246 | 0.0002455 | 0.003262 |
| 352 | REGULATION OF PROTEIN SECRETION | 6 | 389 | 0.0002528 | 0.003342 |
| 353 | EPITHELIUM DEVELOPMENT | 9 | 945 | 0.0002568 | 0.003385 |
| 354 | NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS | 4 | 135 | 0.0002601 | 0.003418 |
| 355 | GLIAL CELL DIFFERENTIATION | 4 | 136 | 0.0002675 | 0.003506 |
| 356 | COGNITION | 5 | 251 | 0.0002694 | 0.003522 |
| 357 | GLAND DEVELOPMENT | 6 | 395 | 0.0002745 | 0.003577 |
| 358 | REGULATION OF CYTOKINE PRODUCTION | 7 | 563 | 0.0002785 | 0.003601 |
| 359 | POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 2 | 11 | 0.0002809 | 0.003601 |
| 360 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 8 | 750 | 0.0002778 | 0.003601 |
| 361 | CHEMICAL HOMEOSTASIS WITHIN A TISSUE | 2 | 11 | 0.0002809 | 0.003601 |
| 362 | REGULATION OF FEVER GENERATION | 2 | 11 | 0.0002809 | 0.003601 |
| 363 | CYCLOOXYGENASE PATHWAY | 2 | 11 | 0.0002809 | 0.003601 |
| 364 | LEUKOCYTE CELL CELL ADHESION | 5 | 255 | 0.0002898 | 0.003694 |
| 365 | FATTY ACID TRANSPORT | 3 | 56 | 0.0002898 | 0.003694 |
| 366 | RESPONSE TO ORGANOPHOSPHORUS | 4 | 139 | 0.0002907 | 0.003696 |
| 367 | ESTABLISHMENT OF PROTEIN LOCALIZATION | 11 | 1423 | 0.0002983 | 0.003782 |
| 368 | CELLULAR CHEMICAL HOMEOSTASIS | 7 | 570 | 0.0003002 | 0.003796 |
| 369 | ESTABLISHMENT OF LOCALIZATION IN CELL | 12 | 1676 | 0.000304 | 0.003834 |
| 370 | RAS PROTEIN SIGNAL TRANSDUCTION | 4 | 143 | 0.0003239 | 0.004073 |
| 371 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 6 | 408 | 0.0003263 | 0.004093 |
| 372 | REGULATION OF GOLGI ORGANIZATION | 2 | 12 | 0.0003366 | 0.004188 |
| 373 | CEREBRAL CORTEX GABAERGIC INTERNEURON DIFFERENTIATION | 2 | 12 | 0.0003366 | 0.004188 |
| 374 | TRACHEA MORPHOGENESIS | 2 | 12 | 0.0003366 | 0.004188 |
| 375 | VASCULOGENESIS | 3 | 59 | 0.0003382 | 0.004197 |
| 376 | REGULATION OF RESPONSE TO WOUNDING | 6 | 413 | 0.0003482 | 0.004309 |
| 377 | REGULATION OF GLUCOSE IMPORT | 3 | 60 | 0.0003555 | 0.004376 |
| 378 | MATERNAL PROCESS INVOLVED IN FEMALE PREGNANCY | 3 | 60 | 0.0003555 | 0.004376 |
| 379 | CARBOXYLIC ACID BIOSYNTHETIC PROCESS | 5 | 270 | 0.0003768 | 0.004613 |
| 380 | ORGANIC ACID BIOSYNTHETIC PROCESS | 5 | 270 | 0.0003768 | 0.004613 |
| 381 | LIPOXYGENASE PATHWAY | 2 | 13 | 0.0003972 | 0.004838 |
| 382 | LYMPH VESSEL MORPHOGENESIS | 2 | 13 | 0.0003972 | 0.004838 |
| 383 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 4 | 152 | 0.0004083 | 0.00496 |
| 384 | RESPONSE TO OSMOTIC STRESS | 3 | 63 | 0.0004105 | 0.004974 |
| 385 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 4 | 154 | 0.000429 | 0.005171 |
| 386 | AMEBOIDAL TYPE CELL MIGRATION | 4 | 154 | 0.000429 | 0.005171 |
| 387 | REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 5 | 278 | 0.0004305 | 0.005176 |
| 388 | REGULATION OF CELL PROJECTION ASSEMBLY | 4 | 155 | 0.0004396 | 0.005272 |
| 389 | CELL CELL ADHESION | 7 | 608 | 0.0004428 | 0.005296 |
| 390 | REGULATION OF RESPIRATORY BURST | 2 | 14 | 0.0004627 | 0.005437 |
| 391 | VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 2 | 14 | 0.0004627 | 0.005437 |
| 392 | REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 2 | 14 | 0.0004627 | 0.005437 |
| 393 | T CELL MIGRATION | 2 | 14 | 0.0004627 | 0.005437 |
| 394 | CARDIOLIPIN METABOLIC PROCESS | 2 | 14 | 0.0004627 | 0.005437 |
| 395 | REGULATION OF PROTEIN KINASE C SIGNALING | 2 | 14 | 0.0004627 | 0.005437 |
| 396 | POSITIVE REGULATION OF SPROUTING ANGIOGENESIS | 2 | 14 | 0.0004627 | 0.005437 |
| 397 | ACID SECRETION | 3 | 66 | 0.0004708 | 0.00549 |
| 398 | CELLULAR RESPONSE TO UV | 3 | 66 | 0.0004708 | 0.00549 |
| 399 | POSITIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 3 | 66 | 0.0004708 | 0.00549 |
| 400 | RESPONSE TO PURINE CONTAINING COMPOUND | 4 | 158 | 0.0004726 | 0.005497 |
| 401 | POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 3 | 68 | 0.0005139 | 0.005963 |
| 402 | POSITIVE REGULATION OF RESPONSE TO WOUNDING | 4 | 162 | 0.0005193 | 0.005996 |
| 403 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 4 | 162 | 0.0005193 | 0.005996 |
| 404 | CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 2 | 15 | 0.0005331 | 0.00605 |
| 405 | REGULATION OF HEAT GENERATION | 2 | 15 | 0.0005331 | 0.00605 |
| 406 | NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS | 2 | 15 | 0.0005331 | 0.00605 |
| 407 | GABAERGIC NEURON DIFFERENTIATION | 2 | 15 | 0.0005331 | 0.00605 |
| 408 | RESPIRATORY BURST | 2 | 15 | 0.0005331 | 0.00605 |
| 409 | REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 2 | 15 | 0.0005331 | 0.00605 |
| 410 | VASCULAR PROCESS IN CIRCULATORY SYSTEM | 4 | 163 | 0.0005315 | 0.00605 |
| 411 | LEUKOCYTE DIFFERENTIATION | 5 | 292 | 0.0005384 | 0.006095 |
| 412 | ACTIN FILAMENT BASED PROCESS | 6 | 450 | 0.0005484 | 0.006194 |
| 413 | CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 3 | 70 | 0.0005596 | 0.006304 |
| 414 | REGULATION OF CELL DEVELOPMENT | 8 | 836 | 0.0005734 | 0.006444 |
| 415 | CYTOSKELETON ORGANIZATION | 8 | 838 | 0.0005825 | 0.006515 |
| 416 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 4 | 167 | 0.0005822 | 0.006515 |
| 417 | ORGAN MORPHOGENESIS | 8 | 841 | 0.0005963 | 0.006638 |
| 418 | RESPONSE TO CARBOHYDRATE | 4 | 168 | 0.0005954 | 0.006638 |
| 419 | REPRODUCTION | 10 | 1297 | 0.0006043 | 0.006711 |
| 420 | POSITIVE REGULATION OF LAMELLIPODIUM ASSEMBLY | 2 | 16 | 0.0006084 | 0.006724 |
| 421 | POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 2 | 16 | 0.0006084 | 0.006724 |
| 422 | NEGATIVE REGULATION OF NEURON DEATH | 4 | 171 | 0.0006363 | 0.006999 |
| 423 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 4 | 171 | 0.0006363 | 0.006999 |
| 424 | MONOCARBOXYLIC ACID BIOSYNTHETIC PROCESS | 4 | 172 | 0.0006504 | 0.007137 |
| 425 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 3 | 74 | 0.0006584 | 0.007178 |
| 426 | REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 74 | 0.0006584 | 0.007178 |
| 427 | HEART DEVELOPMENT | 6 | 466 | 0.0006588 | 0.007178 |
| 428 | STRIATED MUSCLE CELL DIFFERENTIATION | 4 | 173 | 0.0006647 | 0.007226 |
| 429 | REGULATION OF CHROMATIN BINDING | 2 | 17 | 0.0006885 | 0.007365 |
| 430 | POSITIVE REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 2 | 17 | 0.0006885 | 0.007365 |
| 431 | CELLULAR GLUCOSE HOMEOSTASIS | 3 | 75 | 0.0006847 | 0.007365 |
| 432 | ACTIN FILAMENT ORGANIZATION | 4 | 174 | 0.0006792 | 0.007365 |
| 433 | REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 2 | 17 | 0.0006885 | 0.007365 |
| 434 | REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 2 | 17 | 0.0006885 | 0.007365 |
| 435 | MULTI ORGANISM BEHAVIOR | 3 | 75 | 0.0006847 | 0.007365 |
| 436 | GLIOGENESIS | 4 | 175 | 0.0006939 | 0.007405 |
| 437 | EXOCYTOSIS | 5 | 310 | 0.0007055 | 0.007512 |
| 438 | RESPONSE TO CORTICOSTEROID | 4 | 176 | 0.0007088 | 0.00753 |
| 439 | POSITIVE REGULATION OF CELL ACTIVATION | 5 | 311 | 0.0007158 | 0.007587 |
| 440 | RESPONSE TO INORGANIC SUBSTANCE | 6 | 479 | 0.0007605 | 0.008042 |
| 441 | REGULATION OF MITOCHONDRIAL DEPOLARIZATION | 2 | 18 | 0.0007735 | 0.008124 |
| 442 | REGULATION OF CELL MATURATION | 2 | 18 | 0.0007735 | 0.008124 |
| 443 | OVULATION | 2 | 18 | 0.0007735 | 0.008124 |
| 444 | IMMUNE RESPONSE | 9 | 1100 | 0.0007771 | 0.008143 |
| 445 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 5 | 321 | 0.0008252 | 0.008629 |
| 446 | CELLULAR HOMEOSTASIS | 7 | 676 | 0.0008301 | 0.00866 |
| 447 | RESPONSE TO BIOTIC STIMULUS | 8 | 886 | 0.0008389 | 0.008733 |
| 448 | PROSTAGLANDIN BIOSYNTHETIC PROCESS | 2 | 19 | 0.0008632 | 0.008886 |
| 449 | CELLULAR RESPONSE TO FLUID SHEAR STRESS | 2 | 19 | 0.0008632 | 0.008886 |
| 450 | REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 2 | 19 | 0.0008632 | 0.008886 |
| 451 | POSITIVE REGULATION OF LEUKOCYTE CHEMOTAXIS | 3 | 81 | 0.0008569 | 0.008886 |
| 452 | PROSTANOID BIOSYNTHETIC PROCESS | 2 | 19 | 0.0008632 | 0.008886 |
| 453 | PEPTIDYL TYROSINE MODIFICATION | 4 | 186 | 0.0008711 | 0.008948 |
| 454 | SINGLE ORGANISM CELLULAR LOCALIZATION | 8 | 898 | 0.0009155 | 0.009383 |
| 455 | RESPONSE TO STEROID HORMONE | 6 | 497 | 0.000921 | 0.009419 |
| 456 | LEUKOCYTE MEDIATED IMMUNITY | 4 | 189 | 0.0009245 | 0.009434 |
| 457 | REGULATION OF CELLULAR RESPONSE TO STRESS | 7 | 691 | 0.0009438 | 0.009589 |
| 458 | PROTEIN DEPHOSPHORYLATION | 4 | 190 | 0.0009429 | 0.009589 |
| 459 | EMBRYONIC HEMOPOIESIS | 2 | 20 | 0.0009577 | 0.009666 |
| 460 | TRACHEA DEVELOPMENT | 2 | 20 | 0.0009577 | 0.009666 |
| 461 | LYMPH VESSEL DEVELOPMENT | 2 | 20 | 0.0009577 | 0.009666 |
| 462 | RESPONSE TO REACTIVE OXYGEN SPECIES | 4 | 191 | 0.0009614 | 0.009683 |
| 463 | RESPONSE TO METAL ION | 5 | 333 | 0.0009725 | 0.009773 |
| 464 | MONOCARBOXYLIC ACID METABOLIC PROCESS | 6 | 503 | 0.00098 | 0.009809 |
| 465 | REGULATION OF NEURON APOPTOTIC PROCESS | 4 | 192 | 0.0009802 | 0.009809 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | PHOSPHOLIPASE A2 ACTIVITY | 8 | 31 | 3.123e-15 | 2.901e-12 |
| 2 | KINASE ACTIVITY | 19 | 842 | 8.453e-15 | 3.927e-12 |
| 3 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 19 | 992 | 1.608e-13 | 4.978e-11 |
| 4 | RIBONUCLEOTIDE BINDING | 22 | 1860 | 1.571e-11 | 3.648e-09 |
| 5 | PHOSPHOLIPASE ACTIVITY | 8 | 94 | 3.961e-11 | 7.359e-09 |
| 6 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 70 | 2.271e-10 | 3.097e-08 |
| 7 | LIPASE ACTIVITY | 8 | 117 | 2.333e-10 | 3.097e-08 |
| 8 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 6 | 43 | 6.033e-10 | 7.006e-08 |
| 9 | CARBOXYLIC ESTER HYDROLASE ACTIVITY | 8 | 135 | 7.351e-10 | 7.588e-08 |
| 10 | PROTEIN KINASE ACTIVITY | 13 | 640 | 1.259e-09 | 1.17e-07 |
| 11 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 6 | 51 | 1.758e-09 | 1.485e-07 |
| 12 | HYDROLASE ACTIVITY ACTING ON ESTER BONDS | 13 | 739 | 7.105e-09 | 5.501e-07 |
| 13 | CALCIUM DEPENDENT PROTEIN KINASE ACTIVITY | 4 | 12 | 1.196e-08 | 8.545e-07 |
| 14 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 4 | 16 | 4.367e-08 | 2.898e-06 |
| 15 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 10 | 445 | 5.353e-08 | 3.316e-06 |
| 16 | KINASE BINDING | 11 | 606 | 9.188e-08 | 5.335e-06 |
| 17 | ADENYL NUCLEOTIDE BINDING | 16 | 1514 | 1.202e-07 | 6.571e-06 |
| 18 | ENZYME BINDING | 17 | 1737 | 1.279e-07 | 6.602e-06 |
| 19 | CALMODULIN BINDING | 7 | 179 | 1.631e-07 | 7.974e-06 |
| 20 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 1.855e-06 | 8.615e-05 |
| 21 | KINASE REGULATOR ACTIVITY | 6 | 186 | 4.104e-06 | 0.0001815 |
| 22 | PROTEIN KINASE C ACTIVITY | 3 | 16 | 6.244e-06 | 0.0002637 |
| 23 | PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 5 | 178 | 5.384e-05 | 0.002175 |
| 24 | PROTEIN SERINE THREONINE TYROSINE KINASE ACTIVITY | 3 | 39 | 9.82e-05 | 0.003801 |
| 25 | CALCIUM ION BINDING | 8 | 697 | 0.0001688 | 0.006273 |
| 26 | PROTEIN KINASE C BINDING | 3 | 50 | 0.0002069 | 0.007393 |
| 27 | GTPASE ACTIVITY | 5 | 246 | 0.0002455 | 0.008448 |
| 28 | GUANYL NUCLEOTIDE BINDING | 6 | 390 | 0.0002563 | 0.008505 |
| 29 | PHOSPHATIDYLCHOLINE 1 ACYLHYDROLASE ACTIVITY | 2 | 11 | 0.0002809 | 0.008999 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 1.6e-14 | 9.341e-12 |
| 2 | EXTRINSIC COMPONENT OF MEMBRANE | 11 | 252 | 9.236e-12 | 2.697e-09 |
| 3 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 7 | 237 | 1.085e-06 | 0.0001732 |
| 4 | CELL LEADING EDGE | 8 | 350 | 1.187e-06 | 0.0001732 |
| 5 | LAMELLIPODIUM | 6 | 172 | 2.611e-06 | 0.000305 |
| 6 | MAST CELL GRANULE | 3 | 21 | 1.471e-05 | 0.001432 |
| 7 | ACTIN FILAMENT | 4 | 70 | 2.009e-05 | 0.001676 |
| 8 | CELL SUBSTRATE JUNCTION | 7 | 398 | 3.213e-05 | 0.002346 |
| 9 | ACTIN CYTOSKELETON | 7 | 444 | 6.42e-05 | 0.004166 |
| 10 | PERINUCLEAR REGION OF CYTOPLASM | 8 | 642 | 9.578e-05 | 0.005319 |
| 11 | CATALYTIC COMPLEX | 10 | 1038 | 0.0001002 | 0.005319 |
| 12 | ANCHORING JUNCTION | 7 | 489 | 0.0001173 | 0.005709 |
| 13 | PHOSPHATASE COMPLEX | 3 | 48 | 0.0001832 | 0.008228 |
| 14 | CELL JUNCTION | 10 | 1151 | 0.0002336 | 0.009743 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | hsa04370_VEGF_signaling_pathway | 46 | 76 | 1.064e-119 | 1.915e-117 | |
| 2 | hsa04664_Fc_epsilon_RI_signaling_pathway | 28 | 79 | 5.904e-58 | 5.314e-56 | |
| 3 | hsa04662_B_cell_receptor_signaling_pathway | 27 | 75 | 6.024e-56 | 3.614e-54 | |
| 4 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 27 | 136 | 7.221e-48 | 3.249e-46 | |
| 5 | hsa04014_Ras_signaling_pathway | 29 | 236 | 3.04e-45 | 1.094e-43 | |
| 6 | hsa04010_MAPK_signaling_pathway | 29 | 268 | 1.477e-43 | 4.43e-42 | |
| 7 | hsa04660_T_cell_receptor_signaling_pathway | 23 | 108 | 4.255e-41 | 1.094e-39 | |
| 8 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 20 | 95 | 2.048e-35 | 4.609e-34 | |
| 9 | hsa04510_Focal_adhesion | 23 | 200 | 1.839e-34 | 3.679e-33 | |
| 10 | hsa04012_ErbB_signaling_pathway | 19 | 87 | 6.223e-34 | 1.12e-32 | |
| 11 | hsa04730_Long.term_depression | 17 | 70 | 3.502e-31 | 5.73e-30 | |
| 12 | hsa04912_GnRH_signaling_pathway | 17 | 101 | 3.406e-28 | 5.109e-27 | |
| 13 | hsa04062_Chemokine_signaling_pathway | 19 | 189 | 4.506e-27 | 6.239e-26 | |
| 14 | hsa04380_Osteoclast_differentiation | 17 | 128 | 2.524e-26 | 3.245e-25 | |
| 15 | hsa04360_Axon_guidance | 17 | 130 | 3.335e-26 | 4.002e-25 | |
| 16 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 12 | 42 | 4.816e-23 | 5.418e-22 | |
| 17 | hsa04722_Neurotrophin_signaling_pathway | 15 | 127 | 2.034e-22 | 2.154e-21 | |
| 18 | hsa04810_Regulation_of_actin_cytoskeleton | 17 | 214 | 2.209e-22 | 2.209e-21 | |
| 19 | hsa04151_PI3K_AKT_signaling_pathway | 19 | 351 | 7.269e-22 | 6.887e-21 | |
| 20 | hsa04310_Wnt_signaling_pathway | 15 | 151 | 3.035e-21 | 2.732e-20 | |
| 21 | hsa04270_Vascular_smooth_muscle_contraction | 14 | 116 | 4.455e-21 | 3.818e-20 | |
| 22 | hsa04670_Leukocyte_transendothelial_migration | 14 | 117 | 5.053e-21 | 4.134e-20 | |
| 23 | hsa04210_Apoptosis | 13 | 89 | 9.715e-21 | 7.603e-20 | |
| 24 | hsa04720_Long.term_potentiation | 12 | 70 | 4.434e-20 | 3.325e-19 | |
| 25 | hsa04972_Pancreatic_secretion | 13 | 101 | 5.536e-20 | 3.883e-19 | |
| 26 | hsa04910_Insulin_signaling_pathway | 14 | 138 | 5.609e-20 | 3.883e-19 | |
| 27 | hsa00592_alpha.Linolenic_acid_metabolism | 9 | 20 | 1.29e-19 | 8.6e-19 | |
| 28 | hsa04150_mTOR_signaling_pathway | 11 | 52 | 1.474e-19 | 9.479e-19 | |
| 29 | hsa04914_Progesterone.mediated_oocyte_maturation | 12 | 87 | 7.196e-19 | 4.467e-18 | |
| 30 | hsa04973_Carbohydrate_digestion_and_absorption | 10 | 44 | 3.398e-18 | 2.039e-17 | |
| 31 | hsa04620_Toll.like_receptor_signaling_pathway | 12 | 102 | 5.353e-18 | 3.108e-17 | |
| 32 | hsa00591_Linoleic_acid_metabolism | 9 | 30 | 1.081e-17 | 6.079e-17 | |
| 33 | hsa00565_Ether_lipid_metabolism | 9 | 36 | 7.04e-17 | 3.84e-16 | |
| 34 | hsa00590_Arachidonic_acid_metabolism | 10 | 59 | 8.394e-17 | 4.444e-16 | |
| 35 | hsa04975_Fat_digestion_and_absorption | 9 | 46 | 8.102e-16 | 4.167e-15 | |
| 36 | hsa04070_Phosphatidylinositol_signaling_system | 10 | 78 | 1.63e-15 | 8.148e-15 | |
| 37 | hsa00564_Glycerophospholipid_metabolism | 9 | 80 | 1.611e-13 | 7.839e-13 | |
| 38 | hsa04540_Gap_junction | 9 | 90 | 4.826e-13 | 2.286e-12 | |
| 39 | hsa04530_Tight_junction | 9 | 133 | 1.73e-11 | 7.987e-11 | |
| 40 | hsa04630_Jak.STAT_signaling_pathway | 9 | 155 | 6.885e-11 | 3.098e-10 | |
| 41 | hsa04916_Melanogenesis | 8 | 101 | 7.106e-11 | 3.12e-10 | |
| 42 | hsa04020_Calcium_signaling_pathway | 8 | 177 | 6.29e-09 | 2.696e-08 | |
| 43 | hsa04114_Oocyte_meiosis | 6 | 114 | 2.336e-07 | 9.78e-07 | |
| 44 | hsa04520_Adherens_junction | 5 | 73 | 6.877e-07 | 2.813e-06 | |
| 45 | hsa00562_Inositol_phosphate_metabolism | 4 | 57 | 8.848e-06 | 3.539e-05 | |
| 46 | hsa04320_Dorso.ventral_axis_formation | 3 | 25 | 2.528e-05 | 9.891e-05 | |
| 47 | hsa04971_Gastric_acid_secretion | 3 | 74 | 0.0006584 | 0.002522 | |
| 48 | hsa04970_Salivary_secretion | 3 | 89 | 0.001126 | 0.004222 | |
| 49 | hsa04920_Adipocytokine_signaling_pathway | 2 | 68 | 0.01071 | 0.03933 | |
| 50 | hsa04144_Endocytosis | 3 | 203 | 0.01135 | 0.04087 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TBX5-AS1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-450b-5p;hsa-miR-590-5p;hsa-miR-629-3p | 20 | PIK3R1 | Sponge network | -2.108 | 0 | -1.285 | 0 | 0.544 |
| 2 | AC109642.1 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-93-5p;hsa-miR-96-5p | 19 | PIK3R1 | Sponge network | -2.791 | 0 | -1.285 | 0 | 0.529 |
| 3 | RP11-389C8.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 16 | PIK3R1 | Sponge network | -2.039 | 0 | -1.285 | 0 | 0.52 |
| 4 | LINC00968 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 21 | PIK3R1 | Sponge network | -4.19 | 0 | -1.285 | 0 | 0.51 |
| 5 | RP11-720L2.4 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -2.305 | 0 | -1.285 | 0 | 0.496 |
| 6 | LINC00702 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-450b-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 23 | PIK3R1 | Sponge network | -2.856 | 0 | -1.285 | 0 | 0.494 |
| 7 | MAGI2-AS3 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 18 | PIK3R1 | Sponge network | -1.892 | 0 | -1.285 | 0 | 0.486 |
| 8 | LINC00472 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-93-5p | 14 | PIK3R1 | Sponge network | -2.952 | 0 | -1.285 | 0 | 0.458 |
| 9 | FENDRR | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 17 | PIK3R1 | Sponge network | -4.222 | 0 | -1.285 | 0 | 0.438 |
| 10 | AC007743.1 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-424-5p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -2.595 | 0 | -1.285 | 0 | 0.436 |
| 11 | RP11-1024P17.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p | 15 | PIK3R1 | Sponge network | -2.062 | 0 | -1.285 | 0 | 0.418 |
| 12 | RP11-456K23.1 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 23 | PIK3R1 | Sponge network | -1.488 | 0 | -1.285 | 0 | 0.416 |
| 13 | RP11-354E11.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-96-5p | 17 | PIK3R1 | Sponge network | -2.138 | 0 | -1.285 | 0 | 0.41 |
| 14 | RP11-401P9.4 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-590-5p;hsa-miR-93-5p | 14 | PIK3R1 | Sponge network | -3.04 | 0 | -1.285 | 0 | 0.408 |
| 15 | CTD-2013N24.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 18 | PIK3R1 | Sponge network | -1.745 | 0 | -1.285 | 0 | 0.407 |
| 16 | RP11-532F6.3 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -2.028 | 0 | -1.285 | 0 | 0.395 |
| 17 | MIR497HG |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 19 | PIK3R1 | Sponge network | -2.142 | 0 | -1.285 | 0 | 0.391 |
| 18 | RP11-456K23.1 |
hsa-miR-106b-5p;hsa-miR-146b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-29b-3p;hsa-miR-362-5p;hsa-miR-542-3p;hsa-miR-93-5p | 10 | AKT3 | Sponge network | -1.488 | 0 | -1.44 | 0 | 0.389 |
| 19 | RP11-399O19.9 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -0.873 | 0.00072 | -1.285 | 0 | 0.38 |
| 20 | FGF14-AS2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-96-5p | 12 | PIK3R1 | Sponge network | -2.159 | 0 | -1.285 | 0 | 0.378 |
| 21 | HHIP-AS1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-424-5p;hsa-miR-590-3p | 12 | PIK3R1 | Sponge network | -2.807 | 0 | -1.285 | 0 | 0.374 |
| 22 | LINC00092 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | -2.383 | 0 | -1.285 | 0 | 0.369 |
| 23 | RP11-378A13.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -1.713 | 0 | -1.285 | 0 | 0.367 |
| 24 | SH3RF3-AS1 | hsa-miR-128-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-590-5p | 12 | PIK3R1 | Sponge network | -1.583 | 0 | -1.285 | 0 | 0.364 |
| 25 | AC011899.9 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-590-3p | 12 | PIK3R1 | Sponge network | -2.611 | 0 | -1.285 | 0 | 0.364 |
| 26 | AC079630.4 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -3.758 | 0 | -1.285 | 0 | 0.359 |
| 27 | RP5-1042I8.7 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 12 | PIK3R1 | Sponge network | -0.733 | 0.00018 | -1.285 | 0 | 0.358 |
| 28 | AC003090.1 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 14 | PIK3R1 | Sponge network | -3.16 | 2.0E-5 | -1.285 | 0 | 0.358 |
| 29 | GAS6-AS2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-590-5p | 15 | PIK3R1 | Sponge network | -1.761 | 0 | -1.285 | 0 | 0.354 |
| 30 | LINC00968 |
hsa-miR-130b-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-2355-3p;hsa-miR-29a-5p;hsa-miR-590-3p;hsa-miR-9-5p | 10 | NFATC2 | Sponge network | -4.19 | 0 | -1.179 | 0.0004 | 0.353 |
| 31 | LINC00961 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-424-5p;hsa-miR-589-3p;hsa-miR-96-5p | 12 | PIK3R1 | Sponge network | -2.724 | 0 | -1.285 | 0 | 0.346 |
| 32 | AC109642.1 |
hsa-miR-130b-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-2355-3p;hsa-miR-29a-5p;hsa-miR-590-3p;hsa-miR-9-5p | 10 | NFATC2 | Sponge network | -2.791 | 0 | -1.179 | 0.0004 | 0.339 |
| 33 | AC011526.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-93-5p;hsa-miR-96-5p | 10 | PIK3R1 | Sponge network | -2.783 | 0 | -1.285 | 0 | 0.338 |
| 34 | AC004947.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-450b-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -3.94 | 0 | -1.285 | 0 | 0.332 |
| 35 | WDFY3-AS2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-96-5p | 17 | PIK3R1 | Sponge network | -1.297 | 0 | -1.285 | 0 | 0.329 |
| 36 | NR2F1-AS1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 17 | PIK3R1 | Sponge network | -0.427 | 0.1559 | -1.285 | 0 | 0.318 |
| 37 | LINC00607 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-582-5p;hsa-miR-590-5p;hsa-miR-629-3p | 10 | PIK3R1 | Sponge network | -2.277 | 0 | -1.285 | 0 | 0.316 |
| 38 | RP11-462G12.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-582-5p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -1.071 | 0.01175 | -1.285 | 0 | 0.302 |
| 39 | AC016735.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-96-5p | 10 | PIK3R1 | Sponge network | -2.711 | 0.00282 | -1.285 | 0 | 0.298 |
| 40 | RP11-88I21.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | -8.789 | 0 | -1.285 | 0 | 0.297 |
| 41 | RP11-1008C21.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-629-3p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -1.249 | 0 | -1.285 | 0 | 0.297 |
| 42 | RP11-365O16.3 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -2.765 | 0.00017 | -1.285 | 0 | 0.293 |
| 43 | CASC2 | hsa-miR-106a-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | -1.086 | 0 | -1.285 | 0 | 0.29 |
| 44 | RP11-284N8.3 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | -0.761 | 0.05061 | -1.285 | 0 | 0.285 |
| 45 | AF131215.9 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-590-3p | 10 | PIK3R1 | Sponge network | -1.808 | 0 | -1.285 | 0 | 0.282 |
| 46 | RP11-352D13.6 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-424-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 13 | PIK3R1 | Sponge network | -4.634 | 0 | -1.285 | 0 | 0.28 |
| 47 | LIPE-AS1 | hsa-miR-106a-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-590-5p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -0.734 | 0.00039 | -1.285 | 0 | 0.28 |
| 48 | RP11-476D10.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-590-3p;hsa-miR-96-5p | 10 | PIK3R1 | Sponge network | -4.519 | 0 | -1.285 | 0 | 0.279 |
| 49 | BDNF-AS | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -0.568 | 0.02011 | -1.285 | 0 | 0.277 |
| 50 | LINC00443 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p | 10 | PIK3R1 | Sponge network | -3.704 | 0.0003 | -1.285 | 0 | 0.276 |
| 51 | RP11-1008C21.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-629-3p | 12 | PIK3R1 | Sponge network | -1.826 | 3.0E-5 | -1.285 | 0 | 0.272 |
| 52 | SNHG18 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -1.073 | 0.00533 | -1.285 | 0 | 0.27 |
| 53 | C1orf132 | hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-182-5p;hsa-miR-335-3p;hsa-miR-424-5p;hsa-miR-450b-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -0.86 | 0.02429 | -1.285 | 0 | 0.269 |
| 54 | RP1-78O14.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-629-3p | 10 | PIK3R1 | Sponge network | -4.409 | 0 | -1.285 | 0 | 0.264 |
| 55 | RP5-839B4.8 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-335-3p;hsa-miR-629-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -5.037 | 0 | -1.285 | 0 | 0.262 |
| 56 | DIO3OS | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-424-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -1.936 | 0.00085 | -1.285 | 0 | 0.262 |
| 57 | LINC00261 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p | 16 | PIK3R1 | Sponge network | -2.566 | 0.00025 | -1.285 | 0 | 0.259 |
| 58 | LINC00619 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p | 10 | PIK3R1 | Sponge network | -2.307 | 0.02217 | -1.285 | 0 | 0.255 |
| 59 | DNM3OS | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-590-5p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | 0.053 | 0.85755 | -1.285 | 0 | 0.255 |
| 60 | CTA-221G9.11 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -0.645 | 0.06404 | -1.285 | 0 | 0.254 |
| 61 | PCED1B-AS1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-128-3p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-335-3p;hsa-miR-93-5p;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | -0.672 | 0.02084 | -1.285 | 0 | 0.254 |